

# UC Santa Barbara

## UC Santa Barbara Previously Published Works

### Title

A genome-wide screen links peroxisome regulation with Wnt signaling through RNF146 and TNKS/2

### Permalink

<https://escholarship.org/uc/item/187643np>

### Journal

Journal of Cell Biology, 223(10)

### ISSN

0021-9525

### Authors

Vu, Jonathan T  
Tavasoli, Katherine U  
Sheedy, Connor J  
[et al.](#)

### Publication Date

2024-10-07

### DOI

10.1083/jcb.202312069

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives License, available at <https://creativecommons.org/licenses/by-nc-nd/4.0/>

Peer reviewed

1 **Title:** A genome-wide screen links peroxisome regulation with Wnt signaling through RNF146  
2 and TNKS/2

3  
4 **eTOC summary:**

5 The E3 ligase RNF146 regulates peroxisomal-protein import by preventing the PARsylation of  
6 peroxisomal proteins by the poly-ADP ribose polymerases TNKS and TNKS2. Highlighting the  
7 specialization of cell-wide regulatory mechanisms at organelles, peroxisomal recruitment of  
8 TNKS/2 reorients TNKS/2 activity away from components of the Wnt/ $\beta$ -catenin pathway.

9  
10 **Authors:** Jonathan T. Vu<sup>1</sup>, Katherine U. Tavasoli<sup>2</sup>, Connor J. Sheedy<sup>1</sup>, Soham P. Chowdhury<sup>2</sup>,  
11 Lori Mandjikian<sup>2</sup>, Julien Bacal<sup>2</sup>, Meghan A. Morrissey<sup>2</sup>, Chris D. Richardson<sup>2,\*</sup>, Brooke M.  
12 Gardner<sup>2,\*</sup>

13  
14 **Affiliations:** <sup>1</sup>Biomolecular Science and Engineering Program, University of California, Santa  
15 Barbara, Santa Barbara, CA 93106, USA <sup>2</sup>Department of Molecular, Cellular, and  
16 Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106,  
17 USA.

18  
19 \* co-corresponding

20  
21 **Abstract:**

22 Peroxisomes are membrane-bound organelles harboring metabolic enzymes. In humans,  
23 peroxisomes are required for normal development, yet the genes regulating peroxisome  
24 function remain unclear. We performed a genome-wide CRISPRi screen to identify novel factors  
25 involved in peroxisomal homeostasis. We found that inhibition of RNF146, an E3 ligase  
26 activated by poly(ADP-ribose), reduced the import of proteins into peroxisomes. RNF146-  
27 mediated loss of peroxisome import depended on the stabilization and activity of the poly(ADP-  
28 ribose) polymerases TNKS and TNKS2, which bind the peroxisomal membrane protein PEX14.  
29 We propose that RNF146 and TNKS/2 regulate peroxisome import efficiency by PARsylation of  
30 proteins at the peroxisome membrane. Interestingly, we found that the loss of peroxisomes  
31 increased TNKS/2 and RNF146-dependent degradation of non-peroxisomal substrates,  
32 including the beta-catenin destruction complex component AXIN1, which was sufficient to alter  
33 the amplitude of beta-catenin transcription. Together, these observations not only suggest  
34 previously undescribed roles for RNF146 in peroxisomal regulation, but also a novel role in  
35 bridging peroxisome function with Wnt/ $\beta$ -catenin signaling during development.

36  
37 **Introduction**

38 The peroxisome is a membrane-bound organelle that harbors enzymes for specialized  
39 metabolic reactions. The most conserved peroxisomal functions include the beta-oxidation of  
40 fatty acids and regulation of reactive oxygen species [Wanders and Waterham 2006]; however,  
41 cells tune peroxisome function according to need. For example, peroxisomes in the large  
42 intestine of mice contain enzymes for optimal plasmalogen synthesis, while peroxisomes in the  
43 small intestines contain enzymes for optimal beta-oxidation of fatty acids [Morvay et al 2017].  
44 Peroxisome function differentiates alongside cell type: for example, in inner ear cells, sound-  
45 induced autophagy of peroxisomes protects against noise overexposure [Defourny et al 2019],  
46 while in macrophages, peroxisomal metabolism improves phagocytosis [Di Cara et al 2017].  
47 Accordingly, mutations in peroxisomal genes in humans cause a spectrum of Peroxisome  
48 Biogenesis Disorders (PBDs) with phenotypes ranging in severity from early infant mortality,  
49 developmental abnormalities, and liver dysfunction to more specific metabolic syndromes,  
50 sensorineural hearing loss, and retinal degeneration [Braverman et al 2016]. It is therefore

51 important to know both the genes dedicated to peroxisome function in human cells, as well as  
52 the mechanisms by which peroxisome abundance and function are coordinated to meet the  
53 needs of cell.

54 Peroxisomes are made and maintained by approximately 35 PEX proteins which  
55 coordinate the biogenesis of peroxisome membranes and the import of peroxisomal matrix  
56 localized enzymes. Protein import into peroxisomes depends on the presence of peroxisome  
57 structures, as well as on many of the best conserved PEX proteins that ensure the efficiency of  
58 import. Proteins tagged with a C-terminal peroxisomal targeting signal (PTS1) are recognized by  
59 the receptor PEX5, which shuttles the PTS1-cargo to the PEX13/PEX14 docking complex for  
60 import across the peroxisomal membrane [Dammai et al 2001; Skowyra et al. 2022]. After  
61 import, PEX5 is recycled via extraction by PEX1/PEX6/PEX26 from the peroxisomal membrane  
62 following ubiquitination by the PEX2/PEX10/PEX12 E3 ligase complex [Platta et al 2009; Platta  
63 et al 2005]. Cells fine tune peroxisomal protein import, and therefore peroxisome function,  
64 according to need. The repertoire of imported enzymes is regulated through transcription, as  
65 well as ribosomal readthrough that can create protein isoforms with an appended PTS1 tag  
66 [Stiebler et al 2014]. The efficiency of import is also regulated cell-wide, for example,  
67 phosphorylation of PEX5 by ATM, a DNA repair kinase, can induce peroxisome-specific  
68 autophagy in response to oxidative stress [Zhang et al 2015]. Thus, peroxisome homeostasis is  
69 tightly regulated in cells and disruption of this regulation can have severe consequences on  
70 organismal development. However, the full regulatory network that governs the steady state  
71 equilibrium of peroxisome abundance, function, and homeostasis in human cells remains  
72 elusive.

73 Here we performed a genome-wide CRISPRi screen in human cells to identify genes  
74 that influence the import of proteins targeted to peroxisomes. In addition to known *PEX* genes,  
75 we found that knockdown of the E3 ligase RNF146 reduces import of PTS1-tagged proteins into  
76 the peroxisome. RNF146 (Ring Finger Protein 146), also known as Iduna, is a RING-domain E3  
77 ubiquitin ligase that recognizes and ubiquitinates proteins modified by poly(ADP-ribosyl)ation  
78 (PARsylation) [Zhang et al. 2011, DaRosa et al. 2015]. RNF146 interacts directly with poly(ADP-  
79 ribose) polymerases, such as tankyrase-1 and tankyrase-2 (TNKS and TNKS2, referred to here  
80 as TNKS/2 together) [Da Rosa et al. 2015] and PARP1 and PARP2 [Gero et al 2014, Kang et al  
81 2011]. Together, the poly(ADP-ribose) polymerases and RNF146 specifically regulate the  
82 stability of numerous substrates which are first PARsylated and subsequently polyubiquitinated  
83 by RNF146, triggering proteasomal degradation. We found that RNF146-mediated loss of  
84 peroxisomes was dependent on the accumulation of the poly(ADP-ribose) polymerases  
85 TNKS/2, specifically by impairing import into peroxisomes through a mechanism dependent on  
86 TNKS/2's activity as poly(ADP-ribose) polymerases. We thus propose a model in which TNKS/2  
87 binds and PARsylates PEX14 and neighboring proteins, inhibiting the import of PTS1-tagged  
88 proteins.

89 RNF146 and TNKS/2 are better known as co-regulators of protein stability: TNKS/2  
90 binds and PARsylates substrates with a tankyrase-binding motif (TBM), which then triggers  
91 poly-ubiquitination by RNF146 [DaRosa et al 2015]. Known RNF146/TNKS/2 substrates include  
92 AXIN1, BLZF1, 3BP2, and CASC3 [Nie et al 2020, Levaot et al 2011]. Surprisingly, we found  
93 that in a variety of cell lines, a loss of *PEX* genes altered the stability of RNF146/TNKS/2  
94 substrates and could therefore alter the output of downstream signaling pathways, including the  
95 Wnt/beta-catenin pathway. These observations suggest that not only is peroxisome abundance  
96 and function integrally intertwined with cell signaling pathways, but also that peroxisomes  
97 themselves regulate cellular responses to external stimuli.

## 98 **Results**

### 99 **Sequestration of ZeoR in peroxisomes links peroxisome import to viability**

102  
103 Past screens for peroxisomal genes in mammalian cells have relied on peroxisome-  
104 localized enzymatic activity [Zoeller and Raetz 1986, Tsukamoto et al 1990; Morand et al. 1990]  
105 and fluorescence microscopy of PTS1-tagged fluorescent proteins [Ito et al 2000], since  
106 mammalian cells in tissue culture conditions do not require peroxisomes for growth. To facilitate  
107 a CRISPRi screening approach for regulators of peroxisome function, we engineered a cell line,  
108 which we term Pex-ZeoR, in which the efficiency of peroxisome import is linked to cell viability  
109 by fusing the fluorescent marker mVenus and a peroxisomal targeting signal (PTS1) to the gene  
110 encoding resistance to Zeocin, a 1400 Dalton molecule in the bleomycin family that induces  
111 DNA double strand breaks and causes cell death [Murray et al 2014; Drocourt et al 1990]. With  
112 this fusion construct, mVenus-ZeoR-PTS1, cells with functional peroxisomes should sequester  
113 the Zeocin resistance protein (ZeoR), thereby preventing them from neutralizing Zeocin, which  
114 is too large to passively diffuse through peroxisome membranes [Antonenkov and Hiltunen  
115 2006]. By contrast, cells with reduced peroxisome import should accumulate mVenus-ZeoR-  
116 PTS1 in the cytoplasm where it can neutralize Zeocin, conferring a selective advantage in the  
117 presence of Zeocin (**Fig. 1A**). To affirm our strategy, we transduced HCT116 CRISPRi (dCas9-  
118 KRAB) cells [Liang et al 2018; Gilbert et al 2014] to recombinantly express mVenus-ZeoR-  
119 PTS1. As predicted, cells expressing a non-targeting control (NTC) sgRNA had fluorescent  
120 mVenus foci, while cells expressing a *PEX1* targeting sgRNA exhibited diffuse cytosolic  
121 mVenus signal (**Fig. 1B**), consistent with mVenus-ZeoR-PTS1 targeting to the peroxisome. We  
122 then assessed cell growth of the HCT116 CRISPRi Pex-ZeoR cell line over a range of Zeocin  
123 concentrations, finding a clear growth advantage for cells with sgRNAs targeting *PEX1* or *PEX6*  
124 versus NTC at high concentrations of Zeocin (**Fig. S1A**). To identify optimal selection conditions  
125 for the genome-wide screen, we performed a competition assay by co-culturing either *PEX1* or  
126 *PEX6* CRISPRi Pex-ZeoR cells with NTC CRISPRi Pex-ZeoR cells at varying dosages of  
127 Zeocin, and monitoring the abundance of each cell population by flow cytometry. *PEX1* and  
128 *PEX6* knockdown cells started at 5-10% of the cell population and were outcompeted by NTC  
129 cells in conditions without Zeocin. However, they displayed a marked competitive advantage in  
130 the presence of Zeocin (**Fig. 1C, Fig. S1B**). Together, these validation experiments suggest that  
131 peroxisomal sequestration of ZeoR allows for the selection of cells harboring sgRNAs that target  
132 peroxisomal genes.

### 134 A genome-wide CRISPRi screen in Pex-ZeoR cells enriches known *PEX* genes

135  
136 Emboldened, we executed a genome-wide screen with the Pex-ZeoR cell line to identify  
137 novel genes that affect peroxisomal homeostasis. Infection with a genome-wide CRISPRi library  
138 was followed by chronic treatment with or without Zeocin, combined with regular passaging of  
139 cells over 35 days, with samples collected every 7 days for terminal Illumina sequencing  
140 preparation (**Fig. S1C**). We found 1,717 genes that were significantly different ( $p < 0.05$ ) between  
141 the treated and untreated conditions at the day 14 timepoint (**Fig. 1D**). Day 14 serves as the  
142 optimal comparison timepoint because of clear enrichment of the majority of known *PEX* genes  
143 while maintaining sufficient library diversity and replicate quality (**Fig. S1D, S1E**).

144 We observed enrichment of guides targeting known *PEX* genes that facilitate PTS1  
145 import (*PEX5*, *PEX13*, *PEX14*, *PEX2/PEX12*, *PEX1/PEX6*, *PEX26*) and peroxisome membrane  
146 protein targeting (*PEX19*) affirming the efficacy of our strategy (**Fig. 1D**). Guides targeting *PEX7*  
147 and alpha and beta variants of *PEX11* were not strongly enriched, consistent with roles in  
148 recognition of the alternative PTS2 targeting signal (*PEX7*) [Braverman et al 1997], and  
149 peroxisomal membrane elongation (*PEX11*) [Koch et al 2010]. Guides targeting one component  
150 of the peroxisome RING finger complex, *PEX10*, were not enriched compared to the other  
151 constituents, *PEX2* and *PEX12*, and guides targeting other peroxisome membrane biogenesis  
152 factors *PEX3* and *PEX16*, were depleted in the screen (**Fig. 1D, S1E**). While initially

153 unexpected, these results align with recent data that PEX10 and PEX16 CRISPR/Cas  
154 knockouts display only partial peroxisomal import defects (Yagita et al 2022; Ott et al 2023). Of  
155 the known factors regulating peroxisome specific autophagy, such as NBR1, MARCH5,  
156 SQSTM1, HIF1A, and NIX [Kim et al 2008, Deosaran et al 2013, Zheng et al 2022, Wilhelm et al  
157 2022], we found that only guides targeting *HIF1A*, the loss of which stabilizes peroxisomes  
158 [Wilhelm et al 2022], were strongly depleted in our screen. Although most peroxisome-  
159 homeostasis related genes behaved according to our predictions, a handful did not align with  
160 our a priori prognosis. Our results suggest the possibility that not all of the aforementioned  
161 genes are simple or monotonic in their effect on peroxisome import or autophagy, representing  
162 potential new mechanisms for further investigation.

#### 163 164 Guides targeting *RNF146*, *INTS8*, *KCNN4* reduce peroxisomal foci intensity

165  
166 We anticipated that sgRNAs that improve resistance to Zeocin independent of the  
167 peroxisomal localization of ZeoR should also be significantly enriched in our dataset. Thus, to  
168 narrow the candidate list to genes relevant to peroxisomal localization of ZeoR, we filtered our  
169 screen results to exclude factors that modulated resistance to a related DNA damaging agent,  
170 bleomycin [Olivieri et al 2020] (**Fig. S1F**, **Table S1**, Z-score range [-0.5,0.5]). GO analysis of the  
171 remaining genes with a fold change greater than 2 and a Mann-Whitney  $p < 0.05$  revealed a 100-  
172 fold enrichment of GO terms related to protein import into the peroxisome, and a greater than  
173 20-fold enrichment related to RNA cleavage involved in mRNA processing (**Table S2**). We note  
174 that several *PEX* genes (*PEX1*, *PEX6*, *PEX12*) modulate bleomycin resistance, possibly  
175 because there is a direct link between DNA repair and peroxisome biology through localization  
176 of the DNA repair kinase ATM to peroxisome membranes [Zhang et al 2015].

177 We then used fluorescence microscopy of mVenus-PTS1 in the Pex-ZeoR cell line to  
178 assess how knockdown of candidate genes altered peroxisome abundance. For each candidate  
179 gene, we produced two unique constitutive knockdown cell lines per gene and quantified  
180 mVenus-PTS1 foci number, foci and cell area, and foci and cytoplasm fluorescence intensity  
181 using CellProfiler [Stirling et al. 2021]. To estimate the efficiency of peroxisome import while  
182 accounting for different mVenus-PTS1 expression levels, we calculated the ratio of the intensity  
183 of mVenus-PTS1 in peroxisome foci to the intensity of mVenus-PTS1 in the cytoplasm (**Fig. 2A**,  
184 **S2A**, **S2B**). We found that several of the guides enriched by Zeocin selection decreased the  
185 ratio of peroxisomal to cytosolic mVenus-PTS1 intensity, including those targeting the E3 ligase  
186 RNF146, Integrator complex subunit INTS8, and calcium-activated potassium channel KCNN4  
187 (**Fig. 2A**).

#### 188 189 RNF146 regulates peroxisome foci intensity in multiple cell lines

190  
191 Given the magnitude of the impact of the RNF146 knockdown on mVenus-PTS1 foci  
192 (**Fig. 2A**, **2B**), we chose to focus our efforts on characterizing the effects of RNF146 on  
193 peroxisome homeostasis. We first ruled out possible off-target effects of the RNF146 sgRNA by  
194 treating our reporter cell line with RNF146 siRNA, which recapitulated the loss of mVenus foci  
195 signal within 24 hours of siRNA treatment (**Fig. 2C**). To determine if the peroxisomal effect of  
196 RNF146 knockdown was specific to the HCT116 cell line, we created a secondary cell line, the  
197 H4 astrocytoma cancer cell line, harboring the same CRISPRi machinery and our Pex-ZeoR  
198 reporter. We observed significant depletion of mVenus-PTS1 foci intensity in both the HCT116  
199 and H4 *RNF146* and *PEX* knockdown cell lines (**Fig. 2B**, **2D**). The significant depletion of PTS1  
200 foci in two independent cell lines suggests that RNF146 has a bona fide role in regulating  
201 peroxisome homeostasis in human cells.

202 To determine if *RNF146* KD impacted peroxisome biogenesis through an effect on *PEX*  
203 gene expression, we gathered RNA-seq data of *RNF146* KD HCT116 cell mRNA transcripts

204 versus NTC cells. We found that knockdown of *RNF146*, which was confirmed in the data set,  
205 mildly repressed transcription of *PEX3* and *PEX10*. Given that neither *PEX3* nor *PEX10* had  
206 positive phenotype scores in the CRISPRi screen, we found it unlikely that the RNF146  
207 phenotype can be completely explained by these transcriptional changes, thereby indicating a  
208 post-transcriptional role for RNF146 in regard to peroxisomal homeostasis (**Fig. 2E**).  
209

#### 210 RNF146-mediated loss of mVenus-PTS1 foci depends on TNKS/2, but not autophagy

211

212 RNF146 is known to collaborate with poly(ADP-ribose) polymerases to ubiquitinate  
213 PARsylated proteins and target them for degradation. Loss of RNF146 is therefore expected to  
214 stabilize PARsylated substrates, which could act to either inhibit peroxisome biogenesis or  
215 increase peroxisome-specific autophagy. We therefore tested if the observed loss of mVenus-  
216 PTS1 foci in response to RNF146 knockdown depended on changes in the RNF146 partners  
217 TNKS/2. We first assessed TNKS/2 levels in an RNF146 knockdown, and found that knockdown  
218 of RNF146 expression in the HCT116 Pex-ZeoR cell line caused a marked increase in TNKS/2  
219 protein levels (**Fig. 3A**). To test if RNF146's effect on peroxisomes depended on increased  
220 TNKS/2 levels, we performed a dual knockdown assay of *RNF146* and *TNKS/2* in our reporter  
221 cell line. We found that siRNA knockdown of *TNKS* and *TNKS2* in RNF146 CRISPRi cells  
222 rescued the import of mVenus-PTS1 (**Fig. 3A, 3B**) indicating that RNF146's effect on  
223 peroxisomes depended on TNKS/2. In an extended assay, we attempted to swap the dual KD  
224 strategies of RNF146 and TNKS, such that only TNKS (and not TNKS2) was suppressed by  
225 CRISPRi, and RNF146 expression was suppressed by siRNA treatment. We observed that  
226 there was clear rescue in the TNKS CRISPRi and RNF146 siRNA treatment, but that this  
227 rescue was not as complete as the RNF146 CRISPRi and TNKS/2 siRNA treatment, suggesting  
228 that TNKS2 may also play a role in the RNF146 KD phenotype (**Fig. S3A**). These results are  
229 consistent with previous reports that TNKS is significantly stabilized in cells lacking RNF146  
230 [Nie et al 2020]. Although it was previously shown that TNKS mediates peroxisome-specific  
231 autophagy [Li et al 2017], we found that siRNA inhibition of ATG7 did not prevent the  
232 accumulation of TNKS/2 nor the loss of mVenus-PTS1 foci intensity in RNF146 knockdown cells  
233 (**Fig. 3C, 3D**). This lack of dependence on autophagy was further corroborated in multiple cell  
234 lines by the treatment of RNF146 knockdown cells with autophagy inhibitors bafilomycin or  
235 hydroxychloroquine, which, despite preventing LC3BII turnover, did not substantially rescue  
236 peroxisome foci number or intensity relative to control cells (**Fig. S3B-G**). These observations  
237 suggest that while the effect of RNF146 knockdown on peroxisomes depends on TNKS/2, it  
238 does not depend on peroxisome-specific autophagy.  
239

#### 240 Loss of RNF146 specifically inhibits import into peroxisomes

241

242 Since the loss of RNF146 did not appear to induce peroxisome-specific autophagy, we  
243 evaluated whether the loss of RNF146 could specifically impair peroxisome biogenesis at the  
244 stage of protein import into peroxisomes. We performed immunofluorescence microscopy on  
245 the HCT116 and H4 CRISPRi Pex-ZeoR cell lines harboring sgRNAs for *NTC*, *RNF146*, *PEX5*,  
246 and *PEX19*, where *PEX5* and *PEX19* are the receptors for PTS1-tagged matrix protein import  
247 and peroxisomal membrane protein insertion, respectively (**Fig. 4A, S4A**). We found that  
248 knockdown of RNF146 in both HCT116 and H4 cells resembled a *PEX5* knockdown, in which a  
249 peroxisome membrane protein PMP70 remains present and punctate (**Fig. 4A, 4B, S4A, S4B**),  
250 but matrix proteins, both mVenus-PTS1 and catalase, no longer form foci (**Fig. 4A, 4C, Fig.**  
251 **S4A, S4C**) or co-localize with PMP70 (**Fig. S4D**). These observations suggest that loss of  
252 RNF146 inhibits import of *PEX5* client proteins into the peroxisome.

253 Efficient peroxisomal matrix protein import relies on *PEX5* binding to the PTS1-tagged  
254 protein, *PEX5* docking to *PEX13/PEX14* at the peroxisome, and extraction of ubiquitinated

255 PEX5 from the peroxisome membrane by the PEX1/PEX6/PEX26 motor complex for continued  
256 rounds of import. PEX5 is therefore typically distributed between both cytoplasmic and  
257 membrane fractions, with an increased proportion at the peroxisome membrane in mutants of  
258 the ubiquitination and extraction machinery [Platta et al 2005]. To determine if RNF146  
259 knockdown alters the localization of PEX5, we probed for PEX5, mVenus-SKL, and catalase in  
260 soluble and membrane fractions after fractionation. As expected, we observed that PEX5  
261 distributes between both membrane and soluble fractions in wild type cells. Interestingly, a  
262 larger proportion of PEX5 was soluble in RNF146 knockdown cells compared to controls cells  
263 (**Fig. 4D**). This suggests that the impairment of import of peroxisomes may be due to reduced  
264 recruitment of PEX5 and PTS1-cargo to the peroxisome membrane. Additionally, we observed  
265 that the soluble proportion of mVenus-SKL and catalase, both PEX5 client proteins with and  
266 without, respectively, a canonical PTS1 tag, increased in RNF146 and PEX5 knockdown cells,  
267 confirming that RNF146 knockdown also impedes import of endogenous matrix proteins (**Fig.**  
268 **4D**).

#### 269 PARP activity of TNKS/2 impedes import into peroxisomes

271  
272 TNKS/2 contains N-terminal ankyrin repeats that bind substrates with a TBM, a SAM  
273 domain that mediates oligomerization, and a C-terminal poly(ADP-ribose) polymerase domain  
274 [Guettler et al 2011]. There are predicted, conserved TBMs in PEX14, PEX5, PEX19, and  
275 PEX11G [Guettler et al 2011]. Specifically, PEX14 was predicted to have at least 4 purported  
276 TBMs (**Fig. S4E**). We found that TNKS/2 co-immunoprecipitated both FLAG-PEX14 and PEX5  
277 upon RNF146 knockdown (**Fig. 5A**). Additionally, when the reciprocal experiment was  
278 performed, full length FLAG-PEX14 co-immunoprecipitated TNKS/2 and PEX5 in NTC and  
279 RNF146 knockdown cells. Notably, when the TBM3 of PEX14 was mutated, FLAG-PEX14-  
280  $\Delta$ TBM3 cells had reduced affinity for TNKS/2 interaction (**Fig. S4E**). These results suggest  
281 TNKS/2 associates with the peroxisome membrane and peroxisome import machinery, such as  
282 PEX14, upon RNF146 knockdown.

283 To test if RNF146's effect on peroxisome import depended on the PARP activity of  
284 TNKS/2, we tested if the TNKS/2 inhibitors G007LK and XAV939 restored peroxisome foci in  
285 RNF146 knockdown cells (**Fig. 5B, 5C**). We found that TNKS/2 inhibitors partially restored  
286 import of mVenus-PTS1 into foci in RNF146 knockdown cells as judged by the ratio of foci to  
287 cytosolic intensity of mVenus-PTS1, but did not fully recover peroxisome number (**Fig. 5C**). To  
288 determine if TNKS/2 PARsylated proteins at the peroxisome membrane, we immunoprecipitated  
289 PEX14-FLAG. We found that proteins in the PEX14-FLAG elution, which included PEX14-  
290 FLAG, PEX13, PEX5, and TNKS, were PARsylated (**Fig. 5D**). While it is unclear exactly which  
291 proteins are PARsylated, PARsylation was sensitive to TNKS/2 inhibitor XAV939 and amplified  
292 by RNF146 knockdown (**Fig. 5D**). In addition, we found that suppression of RNF146 and the  
293 concomitant increase of TNKS/2 resulted in lowered steady state levels of PEX14 and PEX13,  
294 but not peroxisome membrane protein PMP70, and that this effect was abrogated when TNKS/2  
295 was inhibited by XAV939 (**Fig. 5E**). All together, these observations suggest that TNKS/2's  
296 PARsylation activity is important for RNF146's effect on peroxisomes. We therefore propose a  
297 model in which high levels of active TNKS/2, induced by loss of RNF146, binds PEX14 and  
298 PARsylates proteins at the peroxisome membrane, which inhibits PEX5-mediated protein import  
299 into peroxisomes (**Fig. 5F**).

#### 300 PEX proteins alter RNF146/TNKS/2 activity towards other substrates

301  
302  
303 This model suggests that TNKS/2 binds peroxisome membrane protein PEX14 and can  
304 localize to the peroxisome. Other better-known substrates of TNKS/2, such as BLZF1, which  
305 localizes to the Golgi [Yue et al 2021], and AXIN1, which localizes to centrosomes [Lach et al

2022], have defined locations elsewhere in the cell. We thus wondered if peroxisomal recruitment of TNKS/2 could regulate access to other substrates. To test if the presence of peroxisome membranes and membrane proteins alters TNKS/2 substrate selection, we evaluated the stability of the TNKS/2/RNF146 substrates AXIN1, CASC3, and BLZF1 in cells with knockdown of the peroxisomal membrane protein *PEX14*, the peroxisomal membrane protein chaperone *PEX19*, or a non-targeting control (NTC). We found that AXIN1 and CASC3 levels were significantly depleted in *PEX19* knockdown HCT116 cells, and BLZF1 levels were depleted in both *PEX19* and *PEX14* knockdown HCT116 cells (**Fig. 6A**). Furthermore, *PEX14* and *PEX19* knockdowns also depleted AXIN1 levels in HEK293T, iPSC AICS-0090-391, and H4 CRISPRi cells (**Fig. 6B, 6C, Fig. S5A**), illustrating that this phenomenon is not specific to HCT116 cells. To confirm that the effect of *PEX19* knockdown arises from loss of PEX19, we re-expressed PEX19 using a lentiviral vector to complement the knockdown of endogenous *PEX19*, and observed a rescue of AXIN1 stability (**Fig. 6D**). Additionally, suppression of either *RNF146* or *TNKS/2* mRNA transcripts via siRNA, as well as XAV939-mediated catalytic inhibition of TNKS/2, restored AXIN1 stability in *PEX19* knockdown cells, demonstrating that loss of PEX19 activates RNF146/TNKS/2-mediated destabilization of AXIN1 (**Fig. 6D**). These observations suggest that functional peroxisomes repress TNKS/2 activity towards some substrates, including AXIN1, BLZF1, and CASC3.

324

#### 325 Increased Wnt/beta-catenin signaling in *PEX* knockdown cells

326

327 AXIN1 is the limiting component for the formation of the beta-catenin destruction  
328 complex which induces the phosphorylation and subsequent degradation of the beta-catenin  
329 transcription factor. In canonical Wnt signaling, Wnt ligand binding to the Frizzled receptor  
330 dissociates the beta-catenin destruction complex, allowing beta-catenin to accumulate, enter the  
331 nucleus, and induce transcription of Wnt-responsive genes. The stabilization of AXIN1, such as  
332 by TNKS/2 inhibitors, inhibits Wnt signaling by increasing levels of the destruction complex  
333 [Huang et al 2009]. Since AXIN1 was severely destabilized in *PEX19* knockdown HCT116 cells  
334 and partially destabilized in *PEX14* and *PEX19* knockdown HEK293T, H4, and iPSC AICS-  
335 0090-391 cells, we tested if the knockdown of *PEX* genes can therefore influence the Wnt  
336 signaling pathway using the TOPFlash reporter for beta-catenin transcriptional activity. We  
337 found that HCT116 cells had a greater transcriptional response to Wnt ligand in *PEX14* and  
338 *PEX19* knockdown cells (**Fig. 6E**), as well as increased basal activity. Since HCT116 cells are  
339 derived from a colorectal carcinoma heterozygous for a dominant mutation in beta-catenin that  
340 causes constitutively active beta-catenin-TCF regulated transcription [Morin et al 1997], we also  
341 tested the effect of the PEX knockdowns on the TOPFlash reporter in HEK293T cells. Both  
342 *PEX14* and *PEX19* knockdown HEK293Ts exhibited a partial loss of AXIN1 levels (**Fig. 6B**),  
343 and consistently, also exhibited a greater response to Wnt ligand, though basal levels were not  
344 perturbed (**Fig. 6F**). Our observations show that knockdown of *PEX14* and *PEX19* increases  
345 Wnt signaling consistent with the decreased levels of the core subunit of the beta-catenin  
346 destruction complex, AXIN1.

347

#### 348 **Discussion**

349 Here we describe an approach to link cell viability to peroxisome import efficiency by  
350 sequestering the Zeocin resistance protein in the peroxisome. We use this approach to screen  
351 for novel genes regulating peroxisome import efficiency. In addition to known PEX genes, we  
352 found that the E3 ligase RNF146 regulates peroxisome import through its control of the levels of  
353 the poly(ADP-ribose) polymerases TNKS/2. High levels of TNKS/2, which can bind PEX14 and  
354 possibly other PEX proteins, specifically inhibits import into peroxisomes. In our cell lines,  
355 inhibition of import depends on TNKS/2's poly(ADP-ribose) polymerase activity. We note that Li  
356 and colleagues showed that increased levels of TNKS/2 due to treatment with TNKS/2 inhibitors



357 such as XAV939 could induce peroxisome-specific autophagy in HEK-293T cells; however, this  
358 autophagy does not mediate the loss of mVenus-PTS1 foci in response to RNF146 knockdown  
359 in H4 or HCT116 cells. Instead, we find that TNKS/2's polymerase activity is required for the  
360 observed inhibition of peroxisome import. We therefore propose a model in which loss of  
361 RNF146 stabilizes active TNKS/2, which PARsylates proteins at the peroxisome membrane and  
362 impairs their function in matrix protein import into the peroxisome.

363 This model suggests that any mechanism that inactivates RNF146 will inhibit import into  
364 peroxisomes. In mice, RNF146 transcription is repressed during RANKL-mediated  
365 osteoclastogenesis through an NF- $\kappa$ B binding site [Matsumoto et al 2017], suggesting that  
366 peroxisome import may be coordinated with cell type specification through RNF146 and  
367 TNKS/2. RNF146 activity is also regulated by sumoylation [Li et al 2023], localization to the  
368 nucleus [Gero et al 2014; Sheng et al 2018], and direct interaction with other poly(ADP-ribose)  
369 polymerases such as PARP-1 [Gero et al 2014]. It is therefore possible that temporary  
370 localization of RNF146 to the nucleus in response to DNA damage could impede peroxisome  
371 import, perhaps to increase concentrations of cytosolic catalase to reduce oxidative stress. The  
372 effect of this regulation on TNKS/2 activity and peroxisome import, and the consequences for  
373 RNF146's protective role during DNA damage [Kang et al 2011], oxidative stress [Xu et al  
374 2013], and PARsylation induced cell death [Andrabi et al 2011] warrants further investigation.

375 A second implication of our results is that RNF146/TNKS/2 together may regulate the  
376 stability of substrates at the peroxisome membrane, such as PEX14 itself, or neighboring  
377 proteins. Proteomic studies show that the loss of TNKS significantly stabilizes PEX14 and  
378 SLC27A2, a peroxisomal transporter for long chain fatty acids [Bhardwaj et al 2017], and  
379 indeed, we observed that high levels of TNKS induced by RNF146 knockdown destabilized  
380 PEX14 and PEX13 (Fig. 5D). We did not observe a change in peroxisome protein import or  
381 peroxisome number in response to TNKS knockdown (**Fig. 3B**). However, it is possible that this  
382 may be due to the relatively low levels of expression of endogenous TNKS in the HCT116 cell  
383 line, and in cells with high levels of TNKS, such as the brain, adipose tissue, and endocrine  
384 pancreas [Yeh et al 2009], it is possible that a knockdown of TNKS could improve peroxisome  
385 import and abundance. Indeed, studies of TNKS-deficient mice show that they have increased  
386 fatty acid oxidation, which is consistent with improved peroxisomal function [Yeh et al 2009]. It is  
387 also possible that RNF146/TNKS activity at the peroxisome membrane regulates signaling from  
388 the peroxisome membrane. For example, RNF146/TNKS coordinate the degradation of the  
389 antiviral protein MAVS [Xu et al 2022], which has been shown to localize to both the peroxisome  
390 and mitochondria and initiate disparate signaling pathways upon viral infection [Dixit et al 2010].

391 An intriguing corollary of RNF146/TNKS localization to the peroxisome membrane is the  
392 impact of this localization on its access to other substrates. We found that the knockdown of  
393 different PEX proteins, particularly PEX14, which binds TNKS, and PEX19, which is generally  
394 required for peroxisome membrane protein stability, decreases the stability of RNF146/TNKS  
395 substrates that are not thought to be at the peroxisome. We propose that localization to the  
396 peroxisome membrane acts as a sink for RNF146/TNKS, keeping RNF146/TNKS away from  
397 other substrates such as AXIN1 and Golgi-localized BLZF1, and thereby stabilizing them. In this  
398 model, the absence of peroxisomes allows RNF146/TNKS to re-localize to induce the  
399 degradation of AXIN1 and BLZF1. Indeed, reports in the literature suggest that both RNF146  
400 and TNKS can re-localize in response to perturbations; RNF146 moves between the cytoplasm  
401 and nucleus in response to oxidative stress and DNA damage [Gero et al 2014; Kang et al  
402 2011] and TNKS's diffuse cytosolic localization becomes punctate with treatment with TNKS  
403 inhibitors [Martino-Echarri et al 2016, Thorvaldsen et al 2015] and infection with Sendai virus  
404 [Xu et al 2022].

405 Finally, we demonstrated that the effect of PEX knockdowns on the RNF146/TNKS  
406 substrate AXIN1 was sufficient to alter the transcriptional response to Wnt ligand in two different  
407 cell lines. Our results suggest that peroxisomes may act as signaling platforms that can alter cell

408 fate decisions by impacting Wnt signaling. The most severe forms of Zellweger syndrome have  
409 stereotyped neuronal migration disorders, chondrodysplasia punctata, renal cysts, and  
410 craniofacial dysmorphisms indicating disruptions to normal development [Braverman et al 2016].  
411 Our findings raise the possibility that the perturbation of developmental signaling pathways  
412 contributes to the pathology of Zellweger Spectrum Disorders.  
413  
414

415 **References**

- 416 Andrabi, S.A., H.C. Kang, J.-F. Haince, Y.-I. Lee, J. Zhang, Z. Chi, A.B. West, R.C. Koehler, G.G.  
417 Poirier, T.M. Dawson, and V.L. Dawson. 2011. Iduna protects the brain from glutamate  
418 excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. *Nat*  
419 *Med.* 17:692–699. doi:[10.1038/nm.2387](https://doi.org/10.1038/nm.2387).
- 420 Antonenkov, V.D., and J.K. Hiltunen. 2006. Peroxisomal membrane permeability and solute transfer.  
421 *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.* 1763:1697–1706.  
422 doi:[10.1016/j.bbamcr.2006.08.044](https://doi.org/10.1016/j.bbamcr.2006.08.044).
- 423 Bhardwaj, A., Y. Yang, B. Ueberheide, and S. Smith. 2017. Whole proteome analysis of human  
424 tankyrase knockout cells reveals targets of tankyrase-mediated degradation. *Nat Commun.*  
425 8:2214. doi:[10.1038/s41467-017-02363-w](https://doi.org/10.1038/s41467-017-02363-w).
- 426 Braverman, N., G. Steel, C. Obie, A. Moser, H. Moser, S.J. Gould, and D. Valle. 1997. Human PEX7  
427 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic chondrodysplasia  
428 punctata. *Nat Genet.* 15:369–376. doi:[10.1038/ng0497-369](https://doi.org/10.1038/ng0497-369).
- 429 Braverman, N.E., G.V. Raymond, W.B. Rizzo, A.B. Moser, M.E. Wilkinson, E.M. Stone, S.J.  
430 Steinberg, M.F. Wangler, E.T. Rush, J.G. Hacia, and M. Bose. 2016. Peroxisome biogenesis  
431 disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations,  
432 and treatment guidelines. *Molecular Genetics and Metabolism.* 117:313–321.  
433 doi:[10.1016/j.ymgme.2015.12.009](https://doi.org/10.1016/j.ymgme.2015.12.009).
- 434 Chen, X., and R. Prywes. 1999. Serum-Induced Expression of the *cdc25A* Gene by Relief of E2F-  
435 Mediated Repression. *Molecular and Cellular Biology.* 19:4695–4702.  
436 doi:[10.1128/MCB.19.7.4695](https://doi.org/10.1128/MCB.19.7.4695).
- 437 Chen, S., Zhou, Y., Chen, Y., Gu, J., fastp: an ultra-fast all-in-one FASTQ  
438 preprocessor, *Bioinformatics*, Volume 34, Issue 17, September 2018, Pages i884–  
439 i890, <https://doi.org/10.1093/bioinformatics/bty560>
- 440 Dammai, V., and S. Subramani. 2001. The Human Peroxisomal Targeting Signal Receptor, Pex5p,  
441 Is Translocated into the Peroxisomal Matrix and Recycled to the Cytosol. *Cell.* 105:187–196.  
442 doi:[10.1016/S0092-8674\(01\)00310-5](https://doi.org/10.1016/S0092-8674(01)00310-5).
- 443 DaRosa, P.A., Z. Wang, X. Jiang, J.N. Pruneda, F. Cong, R.E. Klevit, and W. Xu. 2015. Allosteric  
444 activation of the RNF146 ubiquitin ligase by a poly(ADP-ribosyl)ation signal. *Nature.* 517:223–  
445 226. doi:[10.1038/nature13826](https://doi.org/10.1038/nature13826).
- 446 Defourny, J., A. Aghaie, I. Perfettini, P. Avan, S. Delmaghani, and C. Petit. 2019. Pejvakin-mediated  
447 pexophagy protects auditory hair cells against noise-induced damage. *Proc. Natl. Acad. Sci.*  
448 *U.S.A.* 116:8010–8017. doi:[10.1073/pnas.1821844116](https://doi.org/10.1073/pnas.1821844116).
- 449 Deosaran, E., K.B. Larsen, R. Hua, G. Sargent, Y. Wang, S. Kim, T. Lamark, M. Jauregui, K. Law, J.  
450 Lippincott-Schwartz, A. Brech, T. Johansen, and P.K. Kim. 2012. NBR1 acts as an autophagy  
451 receptor for peroxisomes. *Journal of Cell Science.* jcs.114819. doi:[10.1242/jcs.114819](https://doi.org/10.1242/jcs.114819).
- 452 Di Cara, F., A. Sheshachalam, N.E. Braverman, R.A. Rachubinski, and A.J. Simmonds. 2017.  
453 Peroxisome-Mediated Metabolism Is Required for Immune Response to Microbial Infection.  
454 *Immunity.* 47:93-106.e7. doi:[10.1016/j.immuni.2017.06.016](https://doi.org/10.1016/j.immuni.2017.06.016).
- 455 Dixit, E., S. Boulant, Y. Zhang, A.S.Y. Lee, C. Odendall, B. Shum, N. Hacohen, Z.J. Chen, S.P.  
456 Whelan, M. Fransen, M.L. Nibert, G. Superti-Furga, and J.C. Kagan. 2010. Peroxisomes Are  
457 Signaling Platforms for Antiviral Innate Immunity. *Cell.* 141:668–681.  
458 doi:[10.1016/j.cell.2010.04.018](https://doi.org/10.1016/j.cell.2010.04.018).
- 459 Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR.  
460 STAR: ultrafast universal RNA-seq aligner. *Bioinformatics.* 2013 Jan 1;29(1):15-21. doi:  
461 [10.1093/bioinformatics/bts635](https://doi.org/10.1093/bioinformatics/bts635). Epub 2012 Oct 25. PMID: 23104886; PMCID: PMC3530905.
- 462 Drocourt, D., T. Calmels, J.-P. Reynes, M. Baron, and G. Tiraby. 1990. Cassettes of the  
463 *Streptoalloteichus hindustanus ble* gene for transformation of lower and higher eukaryotes to  
464 pleuromycin resistance. *Nucl Acids Res.* 18:4009–4009. doi:[10.1093/nar/18.13.4009](https://doi.org/10.1093/nar/18.13.4009).

466 Gerö, D., P. Szoleczky, A. Chatzianastasiou, A. Papapetropoulos, and C. Szabo. 2014. Modulation  
466 of Poly(ADP-Ribose) Polymerase-1 (PARP-1)-Mediated Oxidative Cell Injury by Ring Finger  
467 Protein 146 (RNF146) in Cardiac Myocytes. *Mol Med.* 20:313–328.  
468 doi:[10.2119/molmed.2014.00102](https://doi.org/10.2119/molmed.2014.00102).

469 Gilbert, L.A., M.A. Horlbeck, B. Adamson, J.E. Villalta, Y. Chen, E.H. Whitehead, C. Guimaraes, B.  
470 Panning, H.L. Ploegh, M.C. Bassik, L.S. Qi, M. Kampmann, and J.S. Weissman. 2014.  
471 Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. *Cell.* 159:647–  
472 661. doi:[10.1016/j.cell.2014.09.029](https://doi.org/10.1016/j.cell.2014.09.029).

473 Guettler, S., J. LaRose, E. Petsalaki, G. Gish, A. Scotter, T. Pawson, R. Rottapel, and F. Sicheri.  
474 2011. Structural Basis and Sequence Rules for Substrate Recognition by Tankyrase Explain the  
475 Basis for Cherubism Disease. *Cell.* 147:1340–1354. doi:[10.1016/j.cell.2011.10.046](https://doi.org/10.1016/j.cell.2011.10.046).

476 Horlbeck, M.A., L.A. Gilbert, J.E. Villalta, B. Adamson, R.A. Pak, Y. Chen, A.P. Fields, C.Y. Park,  
477 J.E. Corn, M. Kampmann, and J.S. Weissman. 2016. Compact and highly active next-  
478 generation libraries for CRISPR-mediated gene repression and activation. *eLife.* 5:e19760.  
479 doi:[10.7554/eLife.19760](https://doi.org/10.7554/eLife.19760).

480 Huang, S.-M.A., Y.M. Mishina, S. Liu, A. Cheung, F. Stegmeier, G.A. Michaud, O. Charlat, E.  
481 Wiellette, Y. Zhang, S. Wiessner, M. Hild, X. Shi, C.J. Wilson, C. Mickanin, V. Myer, A. Fazal, R.  
482 Tomlinson, F. Serluca, W. Shao, H. Cheng, M. Shultz, C. Rau, M. Schirle, J. Schlegl, S.  
483 Ghidelli, S. Fawell, C. Lu, D. Curtis, M.W. Kirschner, C. Lengauer, P.M. Finan, J.A. Tallarico, T.  
484 Bouwmeester, J.A. Porter, A. Bauer, and F. Cong. 2009. Tankyrase inhibition stabilizes axin  
485 and antagonizes Wnt signalling. *Nature.* 461:614–620. doi:[10.1038/nature08356](https://doi.org/10.1038/nature08356).

486 Ito, M., R. Ito, Y. Huang, S. Miura, A. Imamura, Y. Suzuki, and N. Shimozawa. 2000. Rapid isolation  
487 and characterization of CHO mutants deficient in peroxisome biogenesis using the peroxisomal  
488 forms of fluorescent proteins. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.*  
489 1496:232–242. doi:[10.1016/S0167-4889\(00\)00019-7](https://doi.org/10.1016/S0167-4889(00)00019-7).

490 Kampmann, M., M.C. Bassik, and J.S. Weissman. 2014. Functional genomics platform for pooled  
491 screening and generation of mammalian genetic interaction maps. *Nat Protoc.* 9:1825–1847.  
492 doi:[10.1038/nprot.2014.103](https://doi.org/10.1038/nprot.2014.103).

493 Kang, H.C., Y.-I. Lee, J.-H. Shin, S.A. Andrabi, Z. Chi, J.-P. Gagné, Y. Lee, H.S. Ko, B.D. Lee, G.G.  
494 Poirier, V.L. Dawson, and T.M. Dawson. 2011. Iduna is a poly(ADP-ribose) (PAR)-dependent  
495 E3 ubiquitin ligase that regulates DNA damage. *Proc. Natl. Acad. Sci. U.S.A.* 108:14103–14108.  
496 doi:[10.1073/pnas.1108799108](https://doi.org/10.1073/pnas.1108799108).

497 Kim, P.K., D.W. Hailey, R.T. Mullen, and J. Lippincott-Schwartz. 2008. Ubiquitin signals autophagic  
498 degradation of cytosolic proteins and peroxisomes. *Proc. Natl. Acad. Sci. U.S.A.* 105:20567–  
499 20574. doi:[10.1073/pnas.0810611105](https://doi.org/10.1073/pnas.0810611105).

500 Koch, J., K. Pranjic, A. Huber, A. Ellinger, A. Hartig, F. Kragler, and C. Brocard. 2010. PEX11 family  
501 members are membrane elongation factors that coordinate peroxisome proliferation and  
502 maintenance. *Journal of Cell Science.* 123:3389–3400. doi:[10.1242/jcs.064907](https://doi.org/10.1242/jcs.064907).

503 Bach, R.S., C. Qiu, E.Z. Kajbaf, N. Baxter, D. Han, A. Wang, H. Lock, O. Chirikian, B. Pruitt, and M.Z.  
504 Wilson. 2022. Nucleation of the destruction complex on the centrosome accelerates degradation  
505 of  $\beta$ -catenin and regulates Wnt signal transmission. *Proc. Natl. Acad. Sci. U.S.A.*  
506 119:e2204688119. doi:[10.1073/pnas.2204688119](https://doi.org/10.1073/pnas.2204688119).

507 Zevaot, N., O. Voytyuk, I. Dimitriou, F. Sircoulomb, A. Chandrakumar, M. Deckert, P.M.  
508 Krzyzanowski, A. Scotter, S. Gu, S. Janmohamed, F. Cong, P.D. Simoncic, Y. Ueki, J. La Rose,  
509 and R. Rottapel. 2011. Loss of Tankyrase-Mediated Destruction of 3BP2 Is the Underlying  
510 Pathogenic Mechanism of Cherubism. *Cell.* 147:1324–1339. doi:[10.1016/j.cell.2011.10.045](https://doi.org/10.1016/j.cell.2011.10.045).

511 Li, W., Q. Han, Y. Zhu, Y. Zhou, J. Zhang, W. Wu, Y. Li, L. Liu, Y. Qiu, K. Hu, and D. Yin. 2023.  
512 SUMOylation of RNF146 results in Axin degradation and activation of Wnt/ $\beta$ -catenin signaling to  
513 promote the progression of hepatocellular carcinoma. *Oncogene.* 42:1728–1740.  
514 doi:[10.1038/s41388-023-02689-4](https://doi.org/10.1038/s41388-023-02689-4).

515i, X., H. Han, M.-T. Zhou, B. Yang, A.P. Ta, N. Li, J. Chen, and W. Wang. 2017. Proteomic Analysis  
516 of the Human Tankyrase Protein Interaction Network Reveals Its Role in Pexophagy. *Cell*  
517 *Reports*. 20:737–749. doi:[10.1016/j.celrep.2017.06.077](https://doi.org/10.1016/j.celrep.2017.06.077).

518iang, J.R., E. Lingeman, S. Ahmed, and J.E. Corn. 2018. Atlastins remodel the endoplasmic  
519 reticulum for selective autophagy. *Journal of Cell Biology*. 217:3354–3367.  
520 doi:[10.1083/jcb.201804185](https://doi.org/10.1083/jcb.201804185).

521Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq  
522 data with DESeq2. *Genome Biol* **15**, 550 (2014). <https://doi.org/10.1186/s13059-014-0550-8>

523Manner, A., and M. Islinger. 2017. Isolation of Peroxisomes from Rat Liver and Cultured Hepatoma  
524 Cells by Density Gradient Centrifugation. In *Peroxisomes*. M. Schrader, editor. Springer New  
525 York, New York, NY. 1–11.

526Martino-Echarri, E., M.G. Brocardo, K.M. Mills, and B.R. Henderson. 2016. Tankyrase Inhibitors  
527 Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of  $\beta$ -Catenin Degradation-  
528 Competent Axin Puncta. *PLoS ONE*. 11:e0150484. doi:[10.1371/journal.pone.0150484](https://doi.org/10.1371/journal.pone.0150484).

529Matsumoto, Y., J. Larose, O.A. Kent, M. Lim, A. Changoor, L. Zhang, Y. Storozhuk, X. Mao, M.D.  
530 Grynopas, F. Cong, and R. Rottapel. 2017. RANKL coordinates multiple osteoclastogenic  
531 pathways by regulating expression of ubiquitin ligase RNF146. *Journal of Clinical Investigation*.  
532 127:1303–1315. doi:[10.1172/JCI90527](https://doi.org/10.1172/JCI90527).

533Morand, O., L. Allen, R. Zoeller, and C. Raetz. 1990. A rapid selection for animal cell mutants with  
534 defective peroxisomes. *Biochimica et Biophysica Acta (BBA) - General Subjects*. 1034:132–  
535 141. doi:[10.1016/0304-4165\(90\)90066-6](https://doi.org/10.1016/0304-4165(90)90066-6).

536Morin, P.J., A.B. Sparks, V. Korinek, N. Barker, H. Clevers, B. Vogelstein, and K.W. Kinzler. 1997.  
537 Activation of  $\beta$ -Catenin-Tcf Signaling in Colon Cancer by Mutations in  $\beta$ -Catenin or APC.  
538 *Science*. 275:1787–1790. doi:[10.1126/science.275.5307.1787](https://doi.org/10.1126/science.275.5307.1787).

539Morvay, P.L., M. Baes, and P.P. Van Veldhoven. 2017. Differential activities of peroxisomes along  
540 the mouse intestinal epithelium. *Cell Biochemistry & Function*. 35:144–155.  
541 doi:[10.1002/cbf.3255](https://doi.org/10.1002/cbf.3255).

542Murray, V., J.K. Chen, and A.M. Galea. 2014. The anti-tumor drug bleomycin preferentially cleaves  
543 at the transcription start sites of actively transcribed genes in human cells. *Cell. Mol. Life Sci*.  
544 71:1505–1512. doi:[10.1007/s00018-013-1456-4](https://doi.org/10.1007/s00018-013-1456-4).

545Nie, L., C. Wang, N. Li, X. Feng, N. Lee, D. Su, M. Tang, F. Yao, and J. Chen. 2020. Proteome-wide  
546 Analysis Reveals Substrates of E3 Ligase RNF146 Targeted for Degradation. *Molecular &*  
547 *Cellular Proteomics*. 19:2015–2030. doi:[10.1074/mcp.RA120.002290](https://doi.org/10.1074/mcp.RA120.002290).

548Olivieri, M., T. Cho, A. Álvarez-Quilón, K. Li, M.J. Schellenberg, M. Zimmermann, N. Hustedt, S.E.  
549 Rossi, S. Adam, H. Melo, A.M. Heijink, G. Sastre-Moreno, N. Moatti, R.K. Szilard, A. McEwan,  
550 A.K. Ling, A. Serrano-Benitez, T. Ubhi, S. Feng, J. Pawling, I. Delgado-Sainz, M.W. Ferguson,  
551 J.W. Dennis, G.W. Brown, F. Cortés-Ledesma, R.S. Williams, A. Martin, D. Xu, and D.  
552 Durocher. 2020. A Genetic Map of the Response to DNA Damage in Human Cells. *Cell*.  
553 182:481-496.e21. doi:[10.1016/j.cell.2020.05.040](https://doi.org/10.1016/j.cell.2020.05.040).

554Ott, J., J. Sehr, N. Schmidt, W. Schliebs, and R. Erdmann. 2023. Comparison of human PEX  
555 knockout cell lines suggests a dual role of PEX1 in peroxisome biogenesis. *Biological*  
556 *Chemistry*. 404:209–219. doi:[10.1515/hsz-2022-0223](https://doi.org/10.1515/hsz-2022-0223).

557Platta, H.W., F. El Magraoui, B.E. Bäumer, D. Schlee, W. Girzalsky, and R. Erdmann. 2009. Pex2  
558 and Pex12 Function as Protein-Ubiquitin Ligases in Peroxisomal Protein Import. *Molecular and*  
559 *Cellular Biology*. 29:5505–5516. Doi:[10.1128/MCB.00388-09](https://doi.org/10.1128/MCB.00388-09).

560Platta, H.W., S. Grunau, K. Rosenkranz, W. Girzalsky, and R. Erdmann. 2005. Functional role of the  
561 AAA peroxins in dislocation of the cycling PTS1 receptor back to the cytosol. *Nat Cell Biol*.  
562 7:817–822. Doi:[10.1038/ncb1281](https://doi.org/10.1038/ncb1281).

563Pollock, K., M. Raney, I. Collins, and S. Guettler. 2017. Identifying and Validating Tankyrase Binders  
564 and Substrates: A Candidate Approach. In *Poly(ADP-Ribose) Polymerase*. A.V. Tulin, editor.  
565 Springer New York, New York, NY. 445–473.

566 Putri, G., Anders, S., Pyl, P., Pimanda, J., Zanini, F., Analysing high-throughput sequencing data in  
567 Python with HTSeq 2.0, *Bioinformatics*, Volume 38, Issue 10, May 2022, Pages 2943–  
568 2945, <https://doi.org/10.1093/bioinformatics/btac166>

569 Schindelin, J., I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch, S. Preibisch, C.  
570 Rueden, S. Saalfeld, B. Schmid, J.-Y. Tinevez, D.J. White, V. Hartenstein, K. Eliceiri, P.  
571 Tomancak, and A. Cardona. 2012. Fiji: an open-source platform for biological-image analysis.  
572 *Nat Methods*. 9:676–682. doi:[10.1038/nmeth.2019](https://doi.org/10.1038/nmeth.2019).

573 Sheng, Z., Y. Xu, S. Wang, Y. Yuan, T. Huang, and P. Lu. 2018. XPO1-mediated nuclear export of  
574 RNF146 protects from angiotensin II-induced endothelial cellular injury. *Biochemical and*  
575 *Biophysical Research Communications*. 503:1544–1549. Doi:[10.1016/j.bbrc.2018.07.077](https://doi.org/10.1016/j.bbrc.2018.07.077).

576 Kowrya, M.L., and T.A. Rapoport. 2022. PEX5 translocation into and out of peroxisomes drives  
577 matrix protein import. *Molecular Cell*. 82:3209-3225.e7. doi:[10.1016/j.molcel.2022.07.004](https://doi.org/10.1016/j.molcel.2022.07.004).

578 Stiebler, A.C., J. Freitag, K.O. Schink, T. Stehlik, B.A.M. Tillmann, J. Ast, and M. Bölker. 2014.  
579 Ribosomal Readthrough at a Short UGA Stop Codon Context Triggers Dual Localization of  
580 Metabolic Enzymes in Fungi and Animals. *PLoS Genet*. 10:e1004685.  
581 Doi:[10.1371/journal.pgen.1004685](https://doi.org/10.1371/journal.pgen.1004685).

582 Stirling, D.R., M.J. Swain-Bowden, A.M. Lucas, A.E. Carpenter, B.A. Cimini, and A. Goodman. 2021.  
583 CellProfiler 4: improvements in speed, utility and usability. *BMC Bioinformatics*. 22:433.  
584 Doi:[10.1186/s12859-021-04344-9](https://doi.org/10.1186/s12859-021-04344-9).

585 Thorvaldsen, T.E., N.M. Pedersen, E.M. Wenzel, S.W. Schultz, A. Brech, K. Liestøl, J. Waaler, S.  
586 Krauss, and H. Stenmark. 2015. Structure, Dynamics, and Functionality of Tankyrase Inhibitor-  
587 Induced Degradasomes. *Molecular Cancer Research*. 13:1487–1501. Doi:[10.1158/1541-7786.MCR-15-0125](https://doi.org/10.1158/1541-7786.MCR-15-0125).

588 Tsukamoto, T., S. Yokota, and Y. Fujiki. 1990. Isolation and characterization of Chinese hamster  
590 ovary cell mutants defective in assembly of peroxisomes. *The Journal of cell biology*. 110:651–  
591 660. Doi:[10.1083/jcb.110.3.651](https://doi.org/10.1083/jcb.110.3.651).

592 Yeeman, M.T., D.C. Slusarski, A. Kaykas, S.H. Louie, and R.T. Moon. 2003. Zebrafish Prickle, a  
593 Modulator of Noncanonical Wnt/Fz Signaling, Regulates Gastrulation Movements. *Current*  
594 *Biology*. 13:680–685. doi:[10.1016/S0960-9822\(03\)00240-9](https://doi.org/10.1016/S0960-9822(03)00240-9).

595 Wanders, R.J.A., and H.R. Waterham. 2006. Biochemistry of Mammalian Peroxisomes Revisited.  
596 *Annu. Rev. Biochem*. 75:295–332. Doi:[10.1146/annurev.biochem.74.082803.133329](https://doi.org/10.1146/annurev.biochem.74.082803.133329).

597 Wilhelm, L.P., J. Zapata-Muñoz, B. Villarejo-Zori, S. Pellegrin, C.M. Freire, A.M. Toyé, P. Boya, and  
598 I.G. Ganley. 2022. BNIP3L / NIX regulates both mitophagy and pexophagy. *The EMBO Journal*.  
599 41:e111115. Doi:[10.15252/emboj.2022111115](https://doi.org/10.15252/emboj.2022111115).

600 Xu, H., P. Luo, Y. Zhao, M. Zhao, Y. Yang, T. Chen, K. Huo, H. Han, and Z. Fei. 2013. Iduna  
601 protects HT22 cells from hydrogen peroxide-induced oxidative stress through interfering  
602 poly(ADP-ribose) polymerase-1-induced cell death (parthanatos). *Cellular Signalling*. 25:1018–  
603 1026. Doi:[10.1016/j.cellsig.2013.01.006](https://doi.org/10.1016/j.cellsig.2013.01.006).

604 Xu, Y.-R., M.-L. Shi, Y. Zhang, N. Kong, C. Wang, Y.-F. Xiao, S.-S. Du, Q.-Y. Zhu, and C.-Q. Lei.  
605 2022. Tankyrases inhibit innate antiviral response by PARylating VISA/MAVS and priming it for  
606 RNF146-mediated ubiquitination and degradation. *Proc. Natl. Acad. Sci. U.S.A.*  
607 119:e2122805119. Doi:[10.1073/pnas.2122805119](https://doi.org/10.1073/pnas.2122805119).

608 Yagita, Y., Y. Abe, and Y. Fujiki. 2022. De novo formation and maintenance of mammalian  
609 peroxisomes in the absence of PEX16. *Journal of Cell Science*. Jcs.258377.  
610 doi:[10.1242/jcs.258377](https://doi.org/10.1242/jcs.258377).

611 Yeh, T.-Y.J., K.K. Beiswenger, P. Li, K.E. Bolin, R.M. Lee, T.-S. Tsao, A.N. Murphy, A.L. Hevener,  
612 and N.-W. Chi. 2009. Hypermetabolism, Hyperphagia, and Reduced Adiposity in Tankyrase-  
613 Deficient Mice. *Diabetes*. 58:2476–2485. Doi:[10.2337/db08-1781](https://doi.org/10.2337/db08-1781).

614 Yue, X., N. Tiwari, L. Zhu, H.D.T. Ngo, J.-M. Lim, B. Gim, S. Jing, Y. Wang, Y. Qian, and I. Lee.  
615 2021. Tankyrase-1-mediated degradation of Golgin45 regulates glycosyltransferase trafficking

616 and protein glycosylation in Rab2-GTP-dependent manner. *Commun Biol.* 4:1370.  
617 Doi:[10.1038/s42003-021-02899-0](https://doi.org/10.1038/s42003-021-02899-0).  
618 Zhang, J., D.N. Tripathi, J. Jing, A. Alexander, J. Kim, R.T. Powell, R. Dere, J. Tait-Mulder, J.-H. Lee,  
619 T.T. Paull, R.K. Pandita, V.K. Charaka, T.K. Pandita, M.B. Kastan, and C.L. Walker. 2015. ATM  
620 functions at the peroxisome to induce pexophagy in response to ROS. *Nat Cell Biol.* 17:1259–  
621 1269. Doi:[10.1038/ncb3230](https://doi.org/10.1038/ncb3230).  
622 Zhang, Y., S. Liu, C. Mickanin, Y. Feng, O. Charlat, G.A. Michaud, M. Schirle, X. Shi, M. Hild, A.  
623 Bauer, V.E. Myer, P.M. Finan, J.A. Porter, S.-M.A. Huang, and F. Cong. 2011. RNF146 is a  
624 poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. *Nat Cell*  
625 *Biol.* 13:623–629. Doi:[10.1038/ncb2222](https://doi.org/10.1038/ncb2222).  
626 Zheng, J., X. Chen, Q. Liu, G. Zhong, and M. Zhuang. 2022. Ubiquitin ligase MARCH5 localizes to  
627 peroxisomes to regulate pexophagy. *Journal of Cell Biology.* 221:e202103156.  
628 Doi:[10.1083/jcb.202103156](https://doi.org/10.1083/jcb.202103156).  
629 Zoeller, R.A., and C.R. Raetz. 1986. Isolation of animal cell mutants deficient in plasmalogen  
630 biosynthesis and peroxisome assembly. *Proc. Natl. Acad. Sci. U.S.A.* 83:5170–5174.  
631 Doi:[10.1073/pnas.83.14.5170](https://doi.org/10.1073/pnas.83.14.5170).  
632

### 633 **Data Availability**

634 Raw data and count tables from RNAseq (GSE266892) and pooled screen (GSE266855)  
635 experiments have been deposited on GEO with the indicated accession numbers. Microscopy  
636 images are available from authors upon reasonable request.  
637

### 638 **Acknowledgements:**

639 We thank Katelynn Kazane for assistance with engineering CRISPRi cell lines. We thank Amos  
640 Liang and Jacob Corn for Hct116 CRISPRi cells. We thank Diego Acosta-Alvear for H4  
641 CRISPRi cells. We thank Mary West and Pingping He of the High-Throughput Screening Facility  
642 (HTSF) at UC Berkeley for preparation of the pooled CRISPRi library and Jonathan Weissman  
643 for the gift of the pooled library. We thank Griffin Kramer with assistance in data processing. We  
644 thank members of the Gardner and Richardson labs, Joel Rothman, and Chris Hayes for fruitful  
645 discussions. We thank Ron Prywes and Randall Moon for plasmid reagents. Brooke Gardner  
646 acknowledges support from K99/R00GM121880, R35GM146784, and the Searle Scholars  
647 Program. Jonathan Vu acknowledges support from the Connie Frank Fellowship. Lori  
648 Mandjikian acknowledges support from CIRM Educ4. Chris Richardson acknowledges support  
649 from R35 GM142975. The content is solely the responsibility of the authors and does not  
650 necessarily represent the official views of the National Institutes of Health.  
651

### 652 **Conflict of Interest Statement:**

653 The authors declare no competing financial interests.  
654

### 655 **Author Contributions:**

656 J. T. Vu: Conceptualization; Investigation; Formal Analysis; Visualization; Writing – original draft;  
657 Writing – review and editing. K. U. Tavasoli: Investigation; Validation. C. J. Sheedy:  
658 Investigation; Validation. S. P. Chowdhury: Investigation; Validation. L. Mandjikian:  
659 Methodology. J. Bacal: Methodology; Resources. M. A. Morrissey: Resources; Methodology. C.  
660 D. Richardson: Conceptualization; Funding Acquisition; Project Administration; Formal Analysis;  
661 Supervision; Writing – original draft; Writing – review and editing. B. M. Gardner:  
662 Conceptualization; Funding Acquisition; Project Administration; Supervision; Visualization;  
663 Writing – original draft; Writing – review and editing  
664  
665

666

667

668

669



670 **Figures**

671 **Figure 1. A genome-wide screen uncovers genes that regulate peroxisome biology. (A)**  
672 Design of the Pex-ZeoR cell line, which sequesters the Zeocin resistance protein in the  
673 peroxisome matrix. Loss of PEX genes causes cytosolic Zeocin resistance. **(B)** Representative  
674 fluorescence microscopy images of live HCT116 mVenus-ZeoR-PTS1 cells expressing either  
675 NTC or PEX1 sgRNAs. Fusion construct forms puncta in WT but not aperiexosomal (PEX1  
676 knockdown) cells. Fluorescent microscopy data are representative of n=49 images from m=2  
677 biological replicates. Scale bar: 10µm **(C)** Quantification of flow cytometry data of BFP- (NTC)  
678 and BFP+ (PEX1) cells grown in co-culture competition assay over t=11 days in the presence of  
679 0, 25, or 50 ng/uL of Zeocin. Timepoints are taken every t=2 days. Data shown as the mean ±  
680 SD of n=3 biological replicates. **(D)** Volcano plot of NGS data from genome-wide screen with  
681 significance (-log base 10 of p-value, y-axis) and phenotype score (normalized fold change of  
682 cDNA guide count, x-axis) of guides targeting specific genes for cell cultures either untreated  
683 (DMSO mock treated) or treated (50ng/uL Zeocin treated) for 14 days. Red data points  
684 represent known PEX genes and HIF1A. The green data point represents RNF146. Data  
685 displayed was calculated from m=3 guides per gene and n=2 biological replicates.

686 **Figure 2. Peroxisome abundance is regulated locally by RNF146. (A)** CellProfiler  
687 quantification of the ratio of mVenus-PTS1 intensity in foci and in the cytoplasm in fluorescence  
688 microscopy images acquired of live HCT116 Pex-ZeoR cells expressing sgRNAs targeting  
689 various genes. Data per gene constitutes m=2 unique sgRNAs with n=49 images per gene.  
690 Non-targeting control sgRNA shown in yellow, PEX1 sgRNA shown in pink, sgRNAs  
691 significantly different from NTC ( $p < 0.0001$ , independent t-test) are in blue, sgRNA with  $p > 0.05$   
692 are in white. **(B)** Representative fluorescence microscopy images of mVenus expression in  
693 HCT116 Pex-ZeoR cells harboring sgRNAs for NTC, PEX1, or RNF146 and quantification of the  
694 ratio of mVenus-PTS1 foci intensity to mVenus-PTS1 cytosolic intensity. Data is representative  
695 of m= 49 images. n=2 biological replicates. Scale bars: 10 µm. **(C)** Representative fluorescence  
696 microscopy images of mVenus expression in HCT116 Pex-ZeoR cells treated with either  
697 scrambled (scr) siRNA or RNF146 siRNA, and quantification of the ratio of total mVenus-PTS1  
698 foci intensity to mVenus-PTS1 cytosolic intensity. Data is representative of m= 49 images n=2  
699 biological replicates. Scale bar: 10 µm. **(D)** Representative fluorescence microscopy images of  
700 mVenus expression in H4 Pex-ZeoR cells harboring sgRNAs for NTC, PEX1, or RNF146 and  
701 quantification of the ratio of mVenus-PTS1 foci intensity to mVenus-PTS1 cytosolic intensity.  
702 Data is representative of m= 49 images. n=2 biological replicates. Scale bars: 10µm. Asterisks  
703 denote \*\*\*\* $p < 0.0001$ . **(E)** Heatmap of RNA-seq data displaying significant ( $p < 0.05$ ) fold change  
704 of *PEX* gene transcription in RNF146 knockdown cells versus NTC controls. Data is  
705 representative of n=3 biological replicates.

706 **Figure 3. RNF146's effect on peroxisomes is mediated by TNKS/2, but not autophagy. (A)**  
707 Immunoblots for TNKS/2 and ACTB (loading control) in lysate from scrambled or TNKS/2 siRNA  
708 treated HCT116 Pex-ZeoR cells with sgRNAs for either NTC or RNF146. **(B)** Left panel:  
709 Representative mVenus-PTS1 fluorescence microscopy images of either non-targeting control  
710 (NTC) or RNF146 sgRNA cells treated with either scrambled (scr) siRNA or TNKS siRNA. Right  
711 panel: Quantification of mVenus-PTS1 microscopy images in left panel for mVenus-PTS1 foci  
712 intensity versus total cytosol intensity in HCT116 Pex-ZeoR cells. Data is representative of 49  
713 images per condition and 2 biological replicates. Scale bars: 10 µm. **(C)** Immunoblot for  
714 TNKS/2, ATG7, and LC3B in lysate from scrambled or ATG7 siRNA treated HCT116 Pex-ZeoR  
715 cells with sgRNAs for either NTC or RNF146. **(D)** Left panel: Fluorescence microscopy data of  
716 scrambled or ATG7 siRNA treated HCT116 Pex-ZeoR cells with sgRNAs for either non-  
717 targeting control (NTC) or RNF146. m=32 images. n=2 biological replicates. Right panel:

718 Quantification of mVenus-PTS1 microscopy images for mVenus foci intensity versus cytosol  
719 intensity in HCT116 Pex-ZeoR cells. Scale bars: 10 $\mu$ m. All blots are representative of n=3  
720 biological replicates. Asterisks denote p-values \*p <0.05, \*\*\*\*p <0.0001, whereas ns denotes not  
721 significant, calculated by independent t-test.

722 **Figure 4. Loss of RNF146 impairs peroxisome protein import. (A)** Representative  
723 immunofluorescence microscopy images of NTC, RNF146, PEX19, and PEX5 sgRNA  
724 expressing HCT116 Pex-ZeoR cells. mVenus-PTS1 in green, DAPI in blue, PMP70 in magenta.  
725 **(B, C)** Quantification of immunofluorescence microscopy images for percentage foci area of  
726 PMP70 (B) and mVenus-PTS1 (C) versus cytosolic area. m=25 images. n=2 biological  
727 replicates. Asterisks denote p-values \*\*p <0.01, \*\*\*p <0.001, \*\*\*\*p <0.0001, whereas ns denotes  
728 not significant, calculated by independent t-test. **(D)** Immunoblot of HCT116 Pex-ZeoR with  
729 sgRNAs targeting NTC, RNF146, and PEX5. Fractions represent total lysate (T), 20,000xg  
730 supernatant (S), and 20,000xg pellet (P). Densitometry quantification of blots represents the  
731 normalized (to NTC) fold change of the densitometric ratio of soluble vs. pellet fractions (R=S/P)  
732 of selected proteins. Triangle for anti-PEX14 blot denotes the band that disappears with PEX14  
733 sgRNA treatment. All blots are representative of n=3 biological replicates.

734 **Figure 5. TNKS/2 PARP activity impairs peroxisome protein import. (A)** Immunoblots of  
735 anti-TNKS/2 immunoprecipitation fractions from HCT116 Pex-ZeoR cells expressing PEX14  
736 sgRNAs with constitutive re-expression for FLAG-PEX14 treated with either NTC or RNF146  
737 siRNA (10 nM) for 24hrs, detecting TNKS/2, PEX5, and PEX14. **(B)** Representative live-cell  
738 fluorescence microscopy images of NTC and RNF146 sgRNA expressing HCT116 Pex-ZeoR  
739 cells treated with DMSO (mock), 500 nM G007LK, or 10  $\mu$ M XAV939 for 24 hrs. mVenus-PTS1  
740 in green. Scale bar: 10  $\mu$ m. **(C)** Quantification of fluorescence microscopy images for the ratio of  
741 mVenus-PTS1 foci intensity to mVenus-PTS1 cytosolic intensity (left) and the number of foci per  
742 cell (right). m=32 images and n=2 biological replicates. Asterisks denote p-values \*p <0.05, \*\*p  
743 <0.01, \*\*\*p <0.001, \*\*\*\*p <0.0001, whereas ns denotes not significant, calculated by  
744 independent t-test. **(D)** Immunoblots of anti-FLAG immunoprecipitation Total Lysate (input) and  
745 Elution fractions from HCT116 Pex-ZeoR cells expressing NTC sgRNA (lane 4/8) or PEX14  
746 sgRNAs with constitutive re-expression for PEX14-FLAG (lane 1/2/3/5/6/7) treated with either  
747 NTC or RNF146 siRNA (10 nM) for 24hrs, with or without XAV939 (1  $\mu$ M) for 24hrs., and with  
748 carfilzomib (10  $\mu$ M) for 4hrs, detecting FLAG, Poly-(ADP)-ribose (PAR), TNKS/2, PEX5, PEX13,  
749 and PEX14. Representative of n=2 biological replicates. **(E)** Immunoblots of lysates from  
750 HCT116 CRISPRi cells harboring NTC guides treated with either NTC or RNF146 siRNA (10  
751 nM) for 48 hrs, and with or without XAV939 (1  $\mu$ M) for 24hrs. Representative of n=4 biological  
752 replicates. **(F)** Proposed model: loss of RNF146 increases active TNKS/2, which binds PEX14  
753 and PARsylates proteins at the peroxisome membrane impairing peroxisome import.

754 **Figure 6. Peroxisome abundance influences RNF146/TNKS substrate selection. (A-C)**  
755 Immunoblots measuring the abundance of AXIN1, CASC3, and BLZF in **(A)** HCT116 (n=3), **(B)**  
756 HEK293 (n=3), and **(C)** iPSC AICS-0090-391 (n=3) CRISPRi cells with indicated sgRNAs. **(D)**  
757 Western blot measuring abundance of AXIN1 and ACTB (loading control) in HCT116 cells with  
758 indicated sgRNAs, PEX19 knockdown cells are paired with treatments for PEX19 reexpression,  
759 TNKS siRNA (10 nM), RNF146 siRNA 10 nM), or XAV939 (10  $\mu$ M). Blots shown are  
760 representative of n=1 blots. **(E-F)** TOPFlash Dual Luciferase assays measuring the induction of  
761 Wnt signaling to downstream beta-catenin transcription in PEX knockdown HCT116 cells (E)  
762 and HEK293T (F) harboring the indicated sgRNAs and treated with or without 315ng/mL Wnt3a  
763 for 24 hrs (data shown is 48 hours post-transfection with TOPFlash constructs). Luciferase  
764 activity is measured versus a Renilla transfection control and data is normalized to untreated  
765 NTC samples. FOPFlash negative control performed in NTC sgRNA cells. Data is

766 representative of n=3 biological samples. Asterisks denote p-values \*p <0.05, \*\*p <0.01,  
767 calculated by paired t-test.

768

769 **Materials and Methods**

770

771 **Cell Lines, Culture Conditions, Lentiviral Production and Transduction**

772 H4 dCas9-KRAB (a gift from the laboratory of Diego Acosta-Alvear, UCSB), HEK293T, and  
773 HCT116 dCas9-KRAB (a gift from the laboratory of J. Corn, ETH Zürich) cells were cultured in  
774 Dulbecco's Modified Eagle Media (10565018, DMEM, Gibco) supplemented with 10% fetal  
775 bovine serum (FBS, S11150H, R&D Systems), 1% penicillin/streptomycin (15140122, Gibco),  
776 and 2 mM L-Glutamine, and kept at 37°C and 5% CO<sub>2</sub> in a humidified incubator. Generation of  
777 lentivirus was performed by transfecting HEK293T cells with standard delta VPR and VSVG  
778 packaging vectors paired with TransIT-LTI Transfection Reagent (MIR2305, Mirus). Lentivirus  
779 was harvested 72 hrs following transfection and frozen at -80°C.

780

781 Zeocin resistance harboring HCT116 CRISPRi cell lines were constructed by transducing cells  
782 with lentivirus expressing mVenus-ZeoR-PTS1 constructs with either a PGK (pCR2054) or hEF-  
783 1α (pCR2055) promoter and 'spinfected' cells in a centrifuge at 1000 rpm for 2 hrs. ZeoR  
784 expressing cells were single-cell sorted by flow cytometry (Sony SH800S) for mVenus  
785 expression at 488 nm excitation, where modestly fluorescent monoclonal cells were selected for  
786 both promoter types.

787

788 Re-expression constructs were made by Gibson cloning desired CDS sequences into the  
789 pLentiX-CD90 Thy1.1 vector backbone, with subsequent cell sorting of Thy1.1 positive cells by  
790 immunolabeling with CD90.1 Thy-1.1 antibody (17-0900-82, Thermo Scientific).

791

792 For drug treatment conditions, cells were treated with 50 nM bafilomycin (B1793, Sigma-Aldrich)  
793 for 15 hours, 5-10 μM hydroxychloroquine (H0915, Sigma-Aldrich) for 24 hours, 500 nM G007-  
794 LK (S7239, Selleck) for 24 hours, 1 μM XAV939 (575545, EMD Millipore) for 24 hours, and  
795 Carfilzomib (PR-171, Selleck) 10 μM for 4 hours.

796

797 For siRNA treatment conditions, cells were transfected with 10 nM of desired siRNA using  
798 Lipofectamine RNAiMAX (13778150, ThermoFisher) according to the manufacturer's protocol  
799 for 24-48 hrs.

800

801 A list of siRNA and sgRNA sequences used in the manuscript is available in **Table S3**.

802

803

804 **iPS cells**

805 AICS-0090-391 (WTC-CLYBL-dCas9-TagBFP-KRAB-cl391) cells were cultured in 10 ml sterile-  
806 filtered mTeSR-Plus (100-0276, STEMCELL) on a Matrigel-coated plate (354277, Corning) and  
807 grown to 80% confluency, five days post-thaw at 37°C and 5% CO<sub>2</sub> in a humidified incubator.  
808 For routine passaging, at 80% confluency, media was aspirated and cells were washed with 4  
809 ml room temp DPBS prior to dissociation. iPSCs were then treated with 2 ml pre-warmed  
810 Accutase (AT104, Stem Cell Technologies) and the vessel was incubated at 37°C for 10 mins.  
811 Once cells began to detach, 4 mLs DMEM/F12 were added to the Accutase-treated cells and  
812 dissociated cells were triturated. Cells were rinsed with an additional 7 ml of DPBS for a final  
813 wash, and the dissociated cell suspension was transferred to a 15 ml conical tube and  
814 centrifuged at 500g for 5 min at room temp. DMEM/F12/Accutase supernatant was carefully  
815 aspirated and cells were resuspended in 10 ml fresh mTeSR-Plus containing 10μM Y-27632  
816 2HCl (ROCK Inhibitor, S1049, Selleck) (ROCKi) and counted via flow cytometry. Cells were  
817 then seeded into a Matrigel-coated six-well dish at a density of 1.5e+05 per well in 3 ml mTeSR-  
818 Plus containing ROCKi. Old media containing ROCKi was aspirated from each well the next day

819 and replaced with fresh mTeSR1 without ROCKi. mTeSR-Plus was changed daily, and ROCKi  
820 was used for each passaging event, and always removed 24 hours thereafter.

821

### 822 **Genome-wide Pooled CRISPRi Screen and Analysis**

823 HCT116 CRISPRi pCR2054 cells were transduced with lentivirus harboring constructs  
824 expressing sgRNAs from the genome-wide pooled CRISPRi v2 library with 8µg/mL of polybrene  
825 (TR-1003-G, EMD Millipore) at a multiplicity of infection (MOI) of <1. hCRISPRi-v2 library was a  
826 gift from Jonathan Weissman (Addgene ID #83969). Cells were then selected with 1.5 µg/mL  
827 puromycin (A1113803, Gibco) for 1 week in 15 cm dishes and expanded to 3.60 x 10<sup>8</sup> cells to  
828 allow for T0 condition takedowns as well as base seed for Zeocin (R25001, Invitrogen) treated  
829 and untreated samples. Treated cells were subjected to Zeocin 25 ng/µL final concentration and  
830 untreated cells were substituted with DMSO. Cells were maintained at >500X coverage per  
831 library element per replicate per condition throughout the screen. Cells were then cultured for 35  
832 days in 5-Chamber CellStack vessels, splitting cells every 48-72hrs. and harvesting 2.40 x 10<sup>8</sup>  
833 cells every 7 days per condition, where the treated and untreated conditions reached ~8 and  
834 ~16 doublings at day 14, respectively. Genomic DNA was purified using Macherey-Nagel  
835 NucleoSpin Blood XL Maxi Kit (740950.50, Macherey-Nagel) and prepared as previously  
836 described [Kampmann et al 2014] with modifications: Sbf1 (R3642S, NEB) was used instead of  
837 PvuII for the restriction digest. Next-Generation Sequencing (NGS) was performed using an  
838 Illumina NovaSeq SP with 2x50 paired end reads using custom read primers:

839 Read 1:

840 GTGTGTTTTGAGACTATAAGTATCCCTTGGAGAACCACCTTGTTGG

841 Read 2:

842 CTAGCCTTATTTAAACTTGCTATGCTGTTTCCAGCTTAGCTCTTAAAC

843 NGS data was then quantified and phenotype scores were generated using python scripts from  
844 the Horlbeck Lab's ScreenProcessing pipeline as previously described [Horlbeck et al 2016].

845

### 846 **Immunofluorescence Staining**

847 Cells were plated on glass bottom 96-well plates and fixed using 4% paraformaldehyde (15710,  
848 Electron Microscopy Sciences) in DPBS (14190250, Gibco) for 10 minutes and washed twice  
849 with DPBS. Cells were then permeabilized using 0.25% Triton X-100 (A16046.AP, Thermo  
850 Fisher) in DPBS for 10 minutes, blocked with 3% BSA (BP9703100, Fisher Scientific) in PBST  
851 (DPBS, Gibco; 0.1% Tween 20, AAJ20605AP, Thermo Fisher) for 30 minutes, and then probed  
852 with desired antibody in 3% BSA PBST for 1 hour at RT. Cells were then washed 3 times with  
853 PBST and incubated with secondary antibody and DAPI (D1306, Invitrogen) in 3% BSA PBST  
854 for 1 hour at RT in darkness. Cells were then washed 3 times in PBST and stored in DPBS prior  
855 to image acquisition.

856

857 A list of antibodies used in the manuscript is available in **Table S4**.

858

### 859 **Confocal Microscopy and Analysis**

860 Fluorescent image acquisition was performed using a Nikon Eclipse Ti2 configured with a  
861 spinning disk confocal scanner (Yokogawa, CSU-W1), CFI Plan Achromat Lambda D 40X air  
862 objective lens, CFI Achromat TIRF 100X/1.49 oil-immersion objective lens, and NIS-Elements  
863 AR software (Nikon, version 5.31.01). Green (mVenus), blue (BFP, DAPI), red, and far red were  
864 excited with 488, 405, 561, and 640 nm lasers, respectively. Microscopy images were post-  
865 processed using ImageJ/FIJI software (version 2.0.0). Quantification and analysis of microscopy  
866 images was performed using CellProfiler [Stirling et al 2021] (version 4.2.4). For live cell  
867 images, acquired images were thresholded by global minimum cross entropy to select for and  
868 differentiate between cell cytoplasm area and mVenus foci area in an unbiased manner;  
869 downstream mVenus foci number, area, and intensity was measured within a range of size and

870 ROI. For immunofluorescence microscopy, images were processed by, first, defining nuclei  
871 stained by DAPI by adaptive Otsu 3-class thresholding to differentiate between background and  
872 nuclei; second, by expanding from nuclei objects to define cytoplasm based on distance and  
873 Otsu 2-class thresholding and then subtracting nuclei from this area; third, by selecting, within  
874 the cytoplasm area, foci objects for mVenus, Catalase, or PMP70 of a defined size and ROI  
875 determined by adaptive Otsu 3-class thresholding. All of the previously mentioned objects are  
876 then measured for number, area, intensity, and colocalization by Pearson's correlation.  
877

### 878 **Fluorescence-activated Cell Sorting**

879 Flow cytometry was performed using an Attune NxT Flow Cytometer (Invitrogen) or SH800S  
880 (Sony). Excitation wavelengths of 488 nm (530/30 filter) and 405 nm (450/40 filter) were used to  
881 analyze mVenus and BFP expression, respectively. For selection of cells re-expressing PEX14  
882 or PEX19, cells were sorted for Thy1.1 positive cells after immunolabeling with APC-conjugated  
883 CD90.1 Thy-1.1 antibody (17-0900-82, Thermo Scientific) at excitation wavelength of 638 nm  
884 (720/60 filter). FCS data was analyzed and visualized using FlowJo (version 10.6.2).  
885

### 886 **Immunoblotting**

887 Cells were trypsinized (0.05% Trypsin, 25300062, Gibco), quenched, spun down at 300 x g for 5  
888 minutes, decanted, and washed using DPBS (14190250, Gibco). Cells were lysed using RIPA  
889 lysis buffer (0.1% SDS, BP8200100, Fisher Scientific, 1% IPEGAL CA630, 8896, EMD-Millipore;  
890 0.5% sodium deoxycholate, D6750, Sigma, 50mM Tris, BP152-5, Fisher Scientific; 150mM  
891 NaCl, S271-10, Fisher Scientific) with benzonase (101697, EMD Millipore) and protease  
892 inhibitor (78430, Thermo Scientific) for 30 minutes on ice and spun down at 14,000 rpm for 5  
893 minutes and supernatant collected. Total protein concentrations were quantified using Bio-Rad  
894 Protein Assay (5000006, Bio-Rad). Protein samples were normalized to 10-20 µg, mixed with  
895 4X Laemmli sample buffer (62.5mM Tris, 10% glycerol, 1%SDS, 0.005% bromophenol blue)  
896 containing beta-mercaptoethanol (M6250, Sigma-Aldrich), and incubated for 5 minutes at 95  
897 deg C. Samples were loaded and resolved on 4-20% SDS-PAGE gels (#4561095, Bio-Rad),  
898 semi-dry transferred to 0.45 µm LF PVDF membranes (1620264, Bio-Rad), blocked in 5% milk  
899 (Nestle) in TBST (50mM Tris, 150mM NaCl, pH 7.4), and probed with desired antibody in 3%  
900 BSA TBST (BSA, BP9703100, Fisher Scientific) overnight at 4C. Membranes were then washed  
901 and probed with secondary HRP-conjugated antibodies, with visualization of  
902 chemiluminescence using Pierce ECL2 Western Blotting Substrate (PI80196, Thermo Scientific)  
903 on a ChemiDoc MP Imaging System (Bio-Rad). Densitometry was performed using Fiji  
904 [Schindelin et al 2012].  
905

### 906 **TOPFlash**

907 HEK293T ZIM3-dCas9 and HCT116 dCas9-KRAB cells harboring NTC, PEX14, and PEX19  
908 sgRNAs were transfected in 96-well plates by lipofectamine (TransIT LT-1, Mirus). A normalized  
909 55 ng of total plasmid DNA was used at a ratio of 50:5 TOPFlash/FOPFlash:Renilla. Cells were  
910 treated with either BSA or human recombinant WNT3a (5036-WN-010, R&D Systems) 24 hours  
911 later. Cells were then lysed 24 hours after treatment and luciferase activity was measured using  
912 the Dual Luciferase Assay (E1910, Promega) according to manufacturer's protocol, and  
913 luminosity was read out using a microplate reader (SpectraMax M5, Molecular Devices).  
914 Plasmids used were: TopFLASH (Addgene#12456), FopFLASH (Addgene#12457), Renilla  
915 (Addgene#27163). M50 Super 8x TOPFlash and M51 Super 8x FOPFlash (TOPFlash mutant)  
916 were a gift from Randall Moon (Addgene plasmid # 12456, #12457) [Veeman et al 2003]. pRL-  
917 SV40P was a gift from Ron Prywes (Addgene plasmid # 27163) [Chen and Prywes 1999].  
918

### 919 **Subcellular Fractionation**

920 Designated cell lines were harvested at 25-30 million cells (equalized among experimental

921 replicates), spun down, washed, and resuspended in Homogenization Buffer (HB) (250 mM  
922 sucrose, 5 mM MOPS, 1 mM EDTA, 2 mM PMSF, 1 mM DTT, 1 mM  $\epsilon$ -aminocaproic acid, pH  
923 7.4 adjusted with KOH) based on Manner and Islinger et al. 2018. Cells were quickly freeze  
924 thawed and mechanically homogenized via dounce, with a minimum of 10 passes, to lyse the  
925 extracellular membrane while retaining intracellular organelles. Total lysate was collected. The  
926 remainder of the product was centrifuged at 600  $\times$  g max, 10 min, 4  $^{\circ}$ C, the supernatant  
927 collected, pellet was then collected and resuspended with HB, homogenized via dounce, with a  
928 minimum of 10 passes again, centrifuged at 600  $\times$  g max, 10 min, 4  $^{\circ}$ C, supernatant collected  
929 and combined with previously collected supernatant, whereas the remaining pellet is considered  
930 the nuclear pellet. The supernatant was then fractionated at 20,000xg for 30 minutes at 4 $^{\circ}$ C.  
931 The fractionated supernatant was harvested (cytoplasmic fraction), leaving behind the heavy  
932 mitochondrial/light mitochondrial/peroxisomal organellar pellet. The pellet is washed by  
933 resuspension in 1 mL of homogenization buffer, spun down at 20,000xg for 15 minutes at 4 $^{\circ}$ C,  
934 the wash supernatant is discarded, and then washed again in the same manner. The resulting  
935 organellar pellet is lysed by RIPA lysis buffer; this is considered the cell pellet.

936

### 937 **Co-Immunoprecipitation**

938 Designated cell lines were harvested at 10-15 million cells (equalized among experimental  
939 replicates), spun down, and resuspended in LB1 (60 mM HEPES pH 7.6, 150 mM NaCl, 150  
940 mM KCl, 10 mM MgCl<sub>2</sub>, 0.2% IPEGAL CA630 (Sigma), 0.1% sodium deoxycholate (Sigma), 1X  
941 Protease Inhibitor, with or without 1X Benzonase). For FLAG-IP assaying for PARsylation: no  
942 benzonase, 1  $\mu$ M PARGi, and 10  $\mu$ M carfilzomib was included in the LB1. The suspension  
943 quickly undergoes freeze-thaw, is then dounce homogenized (with a minimum of 10 passes),  
944 and then is incubated for 30 minutes at 4 $^{\circ}$ C with inversion. Total lysate samples are acquired  
945 and the remaining lysate is centrifuged for 5 min, 20,000xg at 4 $^{\circ}$ C to separate the sample into  
946 soluble and insoluble fractions. The supernatant (soluble fraction) is collected and spun at  
947 20,000 xg at 4 $^{\circ}$ C for 30 minutes to clear out any remaining insoluble proteins or cell debris, this  
948 is the lysate supernatant. The insoluble fraction is washed with LB1, spun down, decanted, and  
949 resuspended in LB1, this is the pellet. In an optional step, the lysate supernatant is pre-cleared  
950 with protein G agarose beads for 30 minutes at 4 $^{\circ}$ C and washed. For FLAG-IPs, supernatant is  
951 incubated with M2 FLAG conjugated agarose beads (M8823, Millipore) for 2-3 hrs at 4 $^{\circ}$ C with  
952 inversion. For TNKS immunoprecipitations, supernatant is incubated with 10  $\mu$ g of TNKS  
953 antibody (sc-365897, Santa Cruz Biotech) for 3 hrs at 4 $^{\circ}$ C with inversion, and then conjugated  
954 to Protein G Dynabeads (10004D, Invitrogen) for 3hrs. at 4 $^{\circ}$ C with inversion. Beads are then  
955 washed 5X in LB2 buffer (LB1 buffer without protease inhibitors or benzonase) with either  
956 centrifugation or magnetic stand (where applicable). Beads are then eluted using 50  $\mu$ L of  
957 freshly prepared (day of) Elution Buffer (100 mM NaHCO<sub>3</sub>, 1% SDS) at 65 $^{\circ}$ C for 15 min on a  
958 heated shaker (1200 rpm) twice, or for FLAG-IP assaying for PARsylation, 90ul of 300ug/ml  
959 FLAG peptide is dissolved in LB2, and samples are eluted at 4 $^{\circ}$ C shaking at 1100rpm for 30  
960 minutes, then spun down, and supernatant is collected.

961

### 962 **RNA-Seq**

963 HCT116 Pex-ZeoR cell lines harboring either NTC or RNF146 sgRNAs were harvested, spun  
964 down, and RNA was extracted using RNeasy Mini Kit (Qiagen #74104) according to  
965 manufacturer instructions, in triplicate. Purified RNA samples were poly-(A) enriched, reverse  
966 transcribed, and sequenced on an Illumina NovaSeq to produce paired-end 150 bp reads  
967 (Novogene). Raw fastq reads were trimmed using fastp v0.23.2 [Chen et al. 2018], alignment  
968 was done via STAR v 2.7.11a [Dobin et al. 2013], count tables were generated using htseq2 v.  
969 2.0.2 [Putri et al. 2022] and differential expression analysis was performed using the R-package  
970 DESeq2 v. 1.40.1 [Love et al. 2014]. Differential expression comparisons were made between  
971 experimental and nontargeting CRISPRi strains in biological triplicate.





973 **List of Supplementary Materials:**

974

975 Figures S1 to S5

976 Table S1 to S4

977 **Figure S1. (A)** Quantification of cell count by flow cytometry in different concentrations of  
978 Zeocin of HCT116 cells with sgRNAs targeting NTC, PEX1, or PEX6, over 72 hrs. Data is  
979 representative of n=2 biological replicates. Cell count is normalized to untreated. **(B)**  
980 Quantification of flow cytometry data of BFP- (NTC) and BFP+ (PEX6) cells grown in co-culture  
981 competition assay over t=11 days in the presence of 0, 25, or 50 ng/uL of Zeocin. Timepoints  
982 are taken every t=2 days. Data shown as the mean  $\pm$  SD of n=3 biological replicates. **(C)**  
983 Schematic of the CRISPRi screen. Pex-ZeoR cells were transformed with a genome-wide gRNA  
984 library, selected for expression of guides, and split into untreated and +Zeocin growth  
985 conditions. Genomic DNA takedowns for NGS sequencing at t=0 and t=7x for all conditions. **(D)**  
986 Heatmap showing Pearson's correlation coefficient of guide abundance for all library elements  
987 between biological replicates of sequenced timepoints between treated and untreated  
988 conditions. T and Z represent untreated and Zeocin treated conditions, respectively, while  
989 numbers represent timepoint (days). Highlighting indicates comparisons between day 14  
990 samples. **(E)** Fold change of various PEX sgRNA abundances derived from genome-wide  
991 CRISPRi screen comparing Zeocin treated to untreated samples. Highlighting indicates  
992 comparisons between day 14 samples. Y-axis is phenotype score, a measure of fold change of  
993 3 of 5 significant guides per gene. X-axis is time (t) in days. Data is representative of n=2  
994 biological samples. **(F)** Volcano plot of NGS data from genome-wide screen with significance (-  
995 log base 10 of p-value, y-axis) and phenotype score (normalized fold change of cDNA guide  
996 count, x-axis) of guides targeting specific genes for cell cultures either untreated (DMSO mock  
997 treated) or treated (50ng/uL Zeocin treated) for 14 days. Pink data points are output genes  
998 filtered through the Olivieri et al. Bleomycin screen that also have p-value <.05 and minimum  
999 phenotype score of 1. Gray data points are genes that did not pass filter. Red data points  
1000 represent known PEX genes and RNF146. Data displayed was calculated from m=3 guides per  
1001 gene and n=2 biological replicates.

1002 **Supplementary Figure 2. (A)(B)** Additional data as in Figure 2A CellProfiler quantification of  
1003 the ratio of mVenus-PTS1 intensity in foci and in the cytoplasm in fluorescence microscopy  
1004 images acquired of live HCT116 Pex-ZeoR cells expressing sgRNAs targeting various genes.  
1005 **(A)** Positive phenotype score genes from the primary genetic screen. **(B)** Negative phenotype  
1006 score genes from the primary genetic screen. Data per gene constitutes m=2 unique sgRNAs  
1007 with n=49 images per gene. Non-targeting control sgRNA shown in yellow, PEX1 sgRNA shown  
1008 in pink, sgRNAs significantly different from NTC are in blue (p<0.0001, independent t-test) or  
1009 purple (p<0.05, independent t-test), and sgRNAs with p>0.05 are in white.

1010 **Figure S3. (A)** Left Panel: Representative fluorescence microscopy images of NTC, RNF146,  
1011 TNKS sgRNA expressing HCT116 Pex-ZeoR cells treated with either scrambled siRNA  
1012 (scRNA), RNF146 siRNA, or TNKS/2 siRNA (10  $\mu$ M) for 24 hrs. X represents no sample/image.  
1013 Scale bar: 10  $\mu$ m. Right Panel: Quantification of mVenus-PTS1 microscopy images in left panel  
1014 for mVenus foci intensity (peroxisomes) versus total cytosol intensity. Data is representative of  
1015 m=32 images per condition and n=2 biological replicates. **(B)** Left Panel: Representative  
1016 immunofluorescence microscopy images of NTC and RNF146 sgRNA expressing HCT116 Pex-  
1017 ZeoR cells treated with DMSO (mock) or 50 nM Bafilomycin A1 (Baf) for 15 hrs. mVenus-PTS1  
1018 in green, DAPI in blue, and PMP70 in cyan. Scale bar: 10  $\mu$ m. Right panel: Quantification of  
1019 percentage foci area of mVenus-PTS1 and PMP70 versus cytosolic area for m=21 images and  
1020 n=2 biological replicates. **(C)** Immunoblot of TNKS and LC3B of cell lysate from conditions in B.

1021 **(D)** Left Panel: Representative immunofluorescence microscopy images of NTC and RNF146  
1022 sgRNA expressing HCT116 Pex-ZeoR cells treated with DMSO (mock), 5  $\mu$ M  
1023 hydroxychloroquine (HCQ), or 10  $\mu$ M hydroxychloroquine for 24hrs (5  $\mu$ M HCQ not shown).  
1024 mVenus-PTS1 in green, PMP70 in magenta, and DAPI in blue. Scale bar: 10 $\mu$ m. Right panels:  
1025 Quantification of immunofluorescence microscopy images for percentage foci area of mVenus  
1026 and PMP70, respectively, versus cytosolic area. for m=32 images and n=2 biological replicates.  
1027 **(E)** Immunoblots of cellular lysate from (D) against TNKS/2 and LC3B. **(F)** Left Panel:  
1028 Representative fluorescence microscopy images of NTC and RNF146 sgRNA expressing H4  
1029 Pex-ZeoR cells treated with DMSO (mock) or 50 nM Bafilomycin A1 for 15 hrs. Scale bar: 10  
1030  $\mu$ m. Right panel: Quantification of mVenus-PTS1 microscopy images in left panel for mVenus  
1031 foci intensity (peroxisomes) versus total cytosol intensity. Data is representative of m=32  
1032 images per condition and n=2 biological replicates. **(G)** Immunoblots of cellular lysate from left  
1033 panel against TNKS and LC3B. All immunoblots are representative of n=3 independent blots.  
1034 Asterisks denote p-values \*p <0.05, \*\*p <0.01, \*\*\*p <0.001, \*\*\*\*p <0.0001, whereas ns denotes  
1035 not significant, calculated by independent t-test.

1036 **Figure S4. (A)** Left Panel: Representative immunofluorescence microscopy images of NTC,  
1037 RNF146, PEX19, and PEX5 sgRNA expressing H4 Pex-ZeoR cells. mVenus-PTS1 in green,  
1038 DAPI in blue, PMP70 in magenta. **(B, C)** Quantification of immunofluorescence microscopy  
1039 images for percentage foci area of PMP70 **(B)** and mVenus **(C)**, respectively, versus cytosolic  
1040 area. n=25 images. **(D)** Left Panel: Representative immunofluorescence microscopy images  
1041 NTC, RNF146, PEX19, and PEX5 sgRNA expressing cells. Catalase in yellow, DAPI in blue,  
1042 PMP70 in magenta. m=25 images. n=2 biological replicates. Right panel: Quantification of  
1043 Pearson's correlation coefficient of catalase and PMP70 colocalization of microscopy images.  
1044 **(E)** Left Panel: Schematic showing the predicted TBMs of PEX14 with amino acid positions,  
1045 compared to the predicted consensus TBMs of Guettler et al. 2016 and Pollock et al. 2017.  
1046 Red=essential, dark orange=common/variable, light orange=variable,  
1047 yellow=uncommon/accepted, grey=no pattern, G\* = glycine or small non hydrophobic, D\* = D/E  
1048 with some variability, defaced P = no proline. Star = Chosen  $\Delta$ TBM. Right Panel: Immunoblots of  
1049 anti-FLAG immunoprecipitation total and elution fractions from HCT116 Pex-ZeoR cells  
1050 expressing PEX14 sgRNAs with constitutive re-expression of either FLAG-PEX14 (WT) or  
1051 FLAG-PEX14- $\Delta$ TBM3 ( $\Delta$ T), treated with either NTC or RNF146 siRNA (10 nM) for 24hrs,  
1052 detecting TNKS/2, PEX5, and PEX14. Blots are representative of n=3 biological replicates.

1053 **Figure S5. (A)** Immunoblot measuring the abundance of AXIN1 in H4 CRISPRi cells expressing  
1054 sgRNA for NTC, PEX5, PEX14, PEX19, and RNF146.

Figure 1













Figure 2





# Figure 3


## A





## B








## C









## D



# Figure 4




# Figure 5




# Figure 6


## A




## B




## C




## D



## E




## F






# Supplementary Figure 1




# Supplementary Figure 2


## A










## B



# Supplementary Figure 3



# Supplementary Figure 4



# Supplementary Figure 5

